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introduction
The symptoms of lower urinary tract dysfunction can vary from chronic pelvic pain 
to impaired micturition or non-obstructive voiding dysfunction (voiding disorders) 
or overactive bladder syndrome dry and wet (storing disorders). These disorders 
can have a large impact on the patient’s quality of life(1). Unlike in neurogenic 
patients where dysfunction of the peripheral or central nervous system is known to 
cause these symptoms, the aetiology in non-neurogenic patients is in most cases 
unknown. 
Lower urinary tract dysfunction is a common urological problem. Most is known 
about overactive bladder syndrome (OAB), which affects approximately 17% of the 
adult patient population in Europe and the United States(2,3) and has an estimated 
worldwide prevalence of 50-100 million(4). The economic costs are high, but can 
only be estimated since the disorder is often overlooked by physicians and there-
fore underreported(5,6,7). The impact of OAB will probably increase even further in 
the future, since the world population is aging(4) and the prevalence increases with 
age(8).
Lower urinary tract dysfunction is initially treated with conservative therapy (i.e. 
behavioural techniques, physiotherapy, clean intermittent catheterisation and 
pharmacotherapy). When conservative treatment fails, invasive therapy (i.e. blad-
der augmentation, bladder replacement) can be advocated. However, surgery is 
not widespread due to complication and remission rates(9). Neuromodulation has 
been introduced as an alternative treatment for refractory patients who are not 
ready for surgical treatment(10).
Neuromodulation is a physiological process, which inﬂ uences the activity in one 
neural pathway and modulates the pre-existing activity in another by synaptic 
 interaction(11). Different neuromodulative therapies, such as pudendal nerve stimu-
lation, sacral nerve stimulation, and lower limb stimulation, have been developed. 
Their success rates vary(12). 
Percutaneous tibial nerve stimulation (PTNS) is a recently introduced neuromodu-
lative treatment(13), with reported success rates of 21-71%(14-19). The therapy seems 
to be more effective in patients with storing disorders than in patients with voiding 
disorders or chronic pelvic pain. The tibial nerve is a mixed nerve containing motor 
and sensory nerve bundles. The mechanism of action is still unclear, but PTNS is 
supposed to modulate the signals to and from the bladder (S2-S3) via the sacral 
plexus by afferent stimulation(15). 
introduction and outline of the thesis 9
During PTNS treatment the patient is in the frog position (with soles of the feet 
together, and knees abducted and ﬂ exed). A 34-gauge needle is percutaneously 
placed approximately 5 cm cephalad to the medial malleolus, between the pos-
terior margin of the tibia and the soleus muscle. Furthermore, a stick electrode is 
placed on the ipsilateral calcaneus. The needle and electrode are connected to a 
low-voltage (9 V) stimulator (Urgent-PC®, CystoMedix Inc, Anoka, MN, USA). The 
stimulator has ﬁ xed stimulation parameters: pulse width 200 ms, pulse rate 20 
Hz and adjustable stimulation intensity of 0-10 mA.  To conﬁ rm correct placement 
of the needle, the amplitude is slowly increased until ﬂ exion of the big toe and/or 
fanning of the other toes occurs (i.e. motor response). Moreover, patients have a 
sensory response to the stimulation, i.e. a radiating sensation under the sole of the 
foot and/or in the toes(10). The efﬁ cacy of the treatment is usually determined after 
12 weekly 30-minute treatment sessions(10,15-19).
outline of the thesis
This thesis discusses the basic science and applications of tibial nerve stimulation 
in the treatment of refractory overactive bladder syndrome. 
First of all, in chapter 2, the physiology and innervation of the bladder are 
 discussed. After that, the current opinion on the working mechanism of neuro-
modulation is presented in chapter 3. 
Animal studies have demonstrated that afferent pudendal stimulation and sacral 
nerve stimulation can suppress the micturition reﬂ ex(20-23), but for tibial nerve 
stimulation contradicting data have been presented(24,25). chapter 4 investigates 
whether stimulation of the tibial nerve can modulate the micturition reﬂ ex in 
the female cat. Furthermore, it will be investigated whether the sacral plexus is 
involved in the mechanism of action. 
Voiding variables and quality of life have been described to improve signiﬁ cantly in 
PTNS treated patients with refractory overactive bladder wet(10,15). The assumption 
that the improved quality of life in PTNS treated patients is due to improved void-
ing parameters is investigated in chapter 5. 
Patients with overactive bladder syndrome who have been successfully treated with 
PTNS are put on maintenance treatment to maintain the effect(15,16). Most patients 
are treated every 2-3 weeks at the outpatients’ clinic(15). The effects of pausing the 
maintenance treatment for a period of 6 weeks on voiding parameters and quality 
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of life in successfully treated patients are presented in chapter 6. Furthermore, the 
reproducibility of successful treatment in these patients is determined.
Maintenance PTNS is a heavy burden for both patients and hospital facilities, 
since each patient put on a maintenance schedule will visit the outpatients’ depart-
ment at least 20 to 30 times per annum. A subcutaneous implant, Urgent-SQTM
(CystoMedix Inc., Anoka, MN, USA), has been developed to enable self-treatment 
at home. chapter 7 presents the 1-year follow up on feasibility and safety of the 
Urgent-SQTM in the treatment of refractory overactive bladder syndrome. 
In chapter 8 the summary and conclusions of this thesis are presented. A Dutch 
translation can be found in chapter 9. 
The terminology of lower urinary tract dysfunction has been altered during the 
period this thesis was formed. The correct term for urge urinary incontinence and 
urgency/frequency syndrome is now ‘overactive bladder wet and dry’. Since at the 
time these publications were written the new terminology had not been introduced 
yet, the reader may ﬁ nd differing terminology in various chapters of this thesis.
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physiology and innervation of the bladder 
To grasp the physiological background of neuromodulation, some understanding 
of the physiology and innervation of the bladder is essential. The bladder has a 
physiological biphasic cycle consisting of a ﬁ lling phase and a micturition phase, 
which are regulated by parasympathetic, sympathetic, somatic and central nervous 
systems. The innervation of the bladder is presented schematically in ﬁ gure 1.
Sympathetic efferent nerves of the hypogastric plexus originate from the spinal 
 levels Th11-L2(1). These ﬁ bres are active during the ﬁ lling phase of the bladder, which 
results in parasympathetic efferent nerve inhibition(2), relaxation of the bladder 
dome and contraction of the intrinsic sphincter, bladder neck and urethra(3,4). 
Afferent information is conducted via A-delta and C-ﬁ bres. A-delta ﬁ bres conduct 
sensations of urge to void and bladder distension due to bladder ﬁ lling; C-ﬁ bres 
conduct sensations of noxious stimuli(5). Both ﬁ bre types project to the same 
spinal levels, Th11 to L2, via the hypogastric plexus(6,7). Afferent information can be 
projected to both the brain stem and diencephalon(8). C-ﬁ bres are activated during 
pathological circumstances, for instance urinary tract infection and neuropathic 
conditions(9).
Parasympathetic efferent nerves of the pelvic plexus and pelvic nerve originate 
from the spinal levels S2 to S4. These ﬁ bres are active during the micturition phase, 
which results in contraction of the detrusor muscle and relaxation of the intrinsic 
sphincter(10). 
Afferent information via A-delta ﬁ bres and C-ﬁ bres is transported via the pelvic 
plexus and pelvic nerve to the spinal cord (S2-S4)(6,7,11,12). These ﬁ bres are con-
nected, directly or indirectly via interneurons, to efferent ﬁ bres and form a reﬂ ex 
arc(13). The afferent information can be projected as well to the brainstem and 
diencephalon(8).
Somatic ﬁ bres of the pudendal nerve originate from the nucleus of Onuf at the spi-
nal levels S2 to S4 and innervate the rhabdosphincter(14). Activation of these ﬁ bres 
starts micturition and results in relaxation of the sphincter(15). 
Micturition and continence are centrally controlled by the brainstem and dien-
cephalon and are regulated by the midbrain periaqueductal gray, the hypotha-
lamus, and ﬁ nally the medial pontine micturition center or M-region, and the 
lateral pontine continence center or L-region(16). The M and L-region are together 
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known as the ‘on-off’ switch mechanism. The M-region projects to bladder motor 
neurons in the spinal cord(17) and to inhibitory interneurons in the dorsal gray com-
missure, which in turn inhibit sphincter motor neurons in Onuf’s nucleus during 
micturition(18-20). The L-region projects to Onuf’s nucleus(21,22). The periaquaductal 
gray receives bladder ﬁ lling information(13) and projects to the M-region(23). The 
hypothalamus projects directly to the pontine micturition centre and probably 
conveys the ‘safe’ signal to start micturition(16,24,25).
ﬁ gure 1  The nervous systems involved in controlling the bladder 
The bladder is controlled by sympathetic (S), parasympathetic (PS) and somatic nervous systems 
that are regulated by the pontine micturition center (PMC). The periaquaductal gray, hypothala-
mus and frontal cortex are not presented in this ﬁ gure. 
pmc
s
ps
onuf’s
nucleus
bladder
Hypogastric nerve
Pelvic nerve
Pudendal nerve
Urethra
Rhabdosphincter
S2-S4
T11-L2
Spinal cord
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Normal voiding is initiated after adequate input from bladder afferents and 
 demand by the frontal cortex. The M-region is then activated (switched to ‘on’ 
mode) resulting in a coordinated reﬂ ex relaxation of the urethral sphincter 
 muscles, relaxation of the pelvic ﬂ oor and activation of the detrusor muscle(21,24,26). 
This is realized by brainstem nuclei that simultaneously inhibit the somatic motor 
neurons in the sacral spinal cord (Onuf’s nucleus) and activate the sacral para-
sympathetic motor neurons. After the bladder has been emptied, the pontine con-
tinence center (L-region) will be activated and switched to ‘off’ mode. This induces 
pelvic ﬂ oor contraction and an increase in the urethral pressure(21).
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abstract
Purpose
Neuromodulation is a successful treatment for patients with refractory lower 
urinary tract dysfunction. In recent years, more applications of various types and 
ways have been developed and put into clinical practice. Therefore, it is impor-
tant for urologists to know the existing theories on the working mechanisms that 
explain the effect. Although much research has been devoted to this subject during 
the past 35 years, the working mechanism is still unknown. This review presents an 
overview of the different theories and research into the physiological background 
of neuromodulation during the past 3 decades, with emphasis on recent develop-
ments.
Recent ﬁ ndings
Speciﬁ c receptors in the spinal cord have been identiﬁ ed, which are involved in the 
working mechanism of neuromodulation. The maximum effect of neuromodula-
tion is not immediately reached, indicating that neuromodulation induces learning 
changes (i.e. neural plasticity). The carry-over effect could be caused by negative 
modulation of excitatory synapses in the central micturition reﬂ ex pathway.
Summary
Neuromodulation in the treatment of stress incontinence probably induces phy-
siological changes in the sphincter muscles and pelvic ﬂ oor. In the treatment of 
overactive bladder syndrome, nonobstructive voiding dysfunction and chronic pel-
vic pain, the mechanism of action seems to be more complicated. Most likely, it is 
a combination of the different suggested modes of action, involving the neuroaxis 
at different levels.
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introduction
Patients with lower urinary tract dysfunction can have varying complaints from 
voiding disorders (impaired micturition or nonobstructive urinary retention) 
to storing disorders (overactive bladder wet and dry) and chronic pelvic pain. 
Lower urinary tract dysfunction in neurogenic patients is caused by the injury of 
the peripheral or central nervous system; in nonneurogenic patients, it is usually 
unknown.
Neuromodulation offers an alternative treatment for patients who are refractory 
to conservative treatment (behavioural techniques, physiotherapy, clean intermit-
tent catheterization or pharmacotherapy) and not ready for irreversible surgery. 
Neuromodulation is deﬁ ned as the physiological process in which the inﬂ uence 
of the  activity in one neural pathway modulates the pre-existing activity in another 
through synaptic interaction(1). Different therapies, like intravesical stimulation, 
pudendal nerve stimulation, sacral nerve stimulation (SNS) and lower limb stimu-
lation have been developed with varying success rates(2,3). In recent years, more 
applications of various types and ways have been developed and put into medical 
practice(4•-12). As these techniques are put into clinical practice, it is important for 
urologists to know the existing theories on the working mechanisms that explain 
the effect. Although much research has been done, the working mechanisms of 
neuromodulation are still unknown. This review presents an overview of the diffe-
rent theories and research into the physiological background of neuromodulation 
in the past 3 decades, with emphasis on recent developments.
chronic pelvic pain
In the treatment of pain, the working mechanism is believed to be a gate-con-
trol mechanism(13). The gate-control theory states that pain perception does not 
depend on pain receptors sending information to the brain, but on the pattern of 
peripheral nervous input(14). It is believed that a gate-control mechanism is present 
at the spinal segmental level, which can prevent the sensation of pain and the 
reaction to it. Interneurons of the substantia gelatinosa of the spinal cord dorsal 
horn create gating component. Presynaptic inhibition or facilitation of afferent 
 ﬁ bres (ﬁ gure 1) modulates the input to the spinal transmission neurons. Activity 
in A-ﬁ bres excites substantia gelatinosa neurons that, in turn, inhibit synaptic 
transmission and close the gate, which results in hypoalgesia. Hyperalgesia is 
caused by C-ﬁ bre activity resulting in increased presynaptic transmission. Further-
more, the impulses from the dorsal horn are supposed to be controlled by a des-
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cending system containing ﬁ bres from the brainstem, thalamus and limbic lobes.
The discussed gate-control mechanism is believed to be the working mechanism 
for neuromodulation in the treatment of chronic pelvic pain(15-17). Neuromodula-
tion is supposed to restore the control at the spinal segmental ‘gate’ as well as 
at supraspinal sites such as the brainstem and limbic system nuclei. Studies(18,19)
using transcutaneous electrical nerve stimulation (TENS) support the existence of 
descending inhibition, as is supposed in the gate-control theory of Melzack and 
Wall(14). The rostral ventral medulla seems to be involved in this and serotonin and 
opioids are probably used to reduce pain. Finally, it has been suggested that the 
analgesic effects could be mediated by the modulation of autonomic activity(20)
and that adenosine plays a role in the mechanism of action(21,22).
ﬁ gure 1  Schema of the gate-control theory
1Substantia gelatinosa neuron, 2Spinal cord transmission neuron
1 2
–
+
+
+
–
C-ﬁ ber
A-ﬁ ber
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overactive bladder syndrome
Several theories on the working mechanism of the bladder have been proposed. It 
has been suggested that SNS induces pelvic ﬂ oor muscle hypertrophy and chan-
ges the histochemical properties of the muscle, resulting in improved pelvic ﬂ oor 
efﬁ ciency(23). This is supported by animal studies(24) in dogs, which showed hyper-
trophy of striated external sphincter muscle ﬁ bres and increased urethral closure 
pressure during chronic SNS. Afterwards, it was stated that this theory is more 
applicable to the treatment of stress urinary incontinence(25). Direct motor pathway 
stimulation and retrograde spinal motor neuron stimulation in Onuf’s nucleus, or 
central inhibitory pathway activation via afferent pudendal nerve stimulation could, 
however, suppress instable bladder contractions. The latter seems to be more 
logical as neuromodulation is usually applied below the threshold for the motor 
response. Up till now data supporting this assumption have not been presented.
Another theory is activation of sensory nerves(26). This is supported by research 
studying the latency of the motor response (i.e. the anal wink) to SNS demonstra-
ting that the latency was approximately 10 times longer than would be expected 
if the response was mediated by direct motor-nerve stimulation(27). Moreover, the 
latency of cortical responses is shortened during chronic SNS, indicating the acti-
vation of somatosensory afferent ﬁ bres(28).
Activation of the sensory nerves supports the gate-control theory that has been 
used as the working mechanism of neuromodulation in the treatment of chronic 
pain. This is supported by animal studies(29) demonstrating that spino-bulbo-
spinal pathways are involved in the normal micturition reﬂ ex. A-delta bladder 
afferents project to pontine nuclei in the brainstem, which in turn give rise to 
inhibitory and excitatory input to lumbo-sacral reﬂ exes controlling bladder and 
 sphincter function. Sensory input from the pelvic ﬂ oor via large myelinated pu-
dendal ﬁ bres may control erroneous bladder input conveyed by A-type or C-type 
bladder afferents ‘at the gate’ via sacral segmental interneurons and supraspinally 
by way of the spino-bulbo-spinal reﬂ ex system. When a gate-control system is 
attributed to the inhibitory inﬂ uences of interneurons from the somatic pudendal 
nuclei on parasympathetic pelvic nuclei within the spinal cord and brainstem, 
the cause of overactive bladder syndrome could be a deﬁ ciency of the inhibitory 
control systems involving the pudendal afferent nerves(30). Therefore, it has been 
suggested that neuromodulation treats overactive bladder syndrome by restoring 
the balance between the inhibitory and excitatory control systems. The latter could 
be done at various sites in both peripheral and central nervous systems(31). This is 
shown in ﬁ gure 2.
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The supraspinal involvement in the ‘gate-control’ theory is supported by elec-
troencephalogram (EEG) studies during SNS(32). These studies have demonstra-
ted that both short and long latency cortical potentials can be reproduced with a 
maximum at the sensory cortical area, indicating a supraspinal-mediated site of 
modulation, most probably in sensory cortex areas. Moreover, combined photon 
emission tomography (PET) and magnetic resonance imaging (MRI) studies have 
demonstrated that SNS has no effect on the brain areas that are important for the 
micturition itself. The activity of the micturition-dominant right hemisphere is, 
however, relatively reduced and the activity in brain areas that are important for ge-
neral arousal, bladder ﬁ lling sensation and the onset of micturition is decreased(33). 
Furthermore, the maximum beneﬁ cial effect of SNS is reached after several hours 
or days, indicating learning changes in the brain (i.e. neural plasticity)(34). This 
is supported by PET studies demonstrating that only brain areas important for 
motor behaviour learning (i.e. lower trunk motor cortex and the cerebellum) are 
activated during the ﬁ rst hours of SNS. After the initial period, the pelvic ﬂ oor and 
abdominal motor cortical areas are more easily excited and the effects of SNS are 
prolonged and pronounced(34). Finally, these studies showed that SNS activates the 
mid cingulated gyrus, which could result in a temporarily increased awareness of 
bladder ﬁ lling.
Another mechanism of action of SNS could be the activation of the hypogastric 
sympathetic nerves, which have an inhibitory effect on the parasympathetic ﬁ bres 
at the pelvic ganglia(35). Furthermore, recent studies have indicated that non-
N-methyl-D-aspartate (non-NMDA) receptors(36••) and proton-sensitive and heat-
sensitive vanilloid receptors(37) are involved in the working mechanism of SNS.
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ﬁ gure 2   The nervous systems involved in controlling the bladder and the working mecha-
nism of neuromodulation
The bladder is controlled by sympathetic (S), parasympathetic (PS) and somatic nervous systems 
that are regulated by the pontine micturition center (PMC). Micturition (bladder contraction) is 
facilitated by activation of the parasympathetic system through the pelvic nerve (S2-S4). Conti-
nence is facilitated by both the sympathetic system through the hypogastric nerve (T11-L2, bladder 
relaxation and internal sphincter contraction) and the somatic system trough the pudendal nerve 
(S2-S4, rhabdosphincter contraction). It is unclear whether the tibial nerve (L4-S3) modulates the 
bladder function through the pelvic nerve or pudendal nerve or both.
For pudendal nerve stimulation, it has been demonstrated that spinal pathways 
connect somatic and autonomic reﬂ ex circuits, which have mostly an inhibitory 
mode of action. Two mechanisms have been identiﬁ ed that have their afferent limb 
in the pudendal nerve and inhibit the bladder directly. At low bladder pressure, 
bladder contractions are suppressed via sympathetic hypogastric nerves, whereas 
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at high bladder pressure, parasympathetic pelvic excitatory neurons are activa-
ted, resulting in central inhibition(38,39). Furthermore, pudendal nerve stimulation 
results in the activation of the sympathetic hypogastric nerves and inhibits the 
excitatory pelvic efferent outﬂ ow to the bladder at the ganglionic level(40). This 
could be explained by the presence of a gate-control mechanism at the spinal cord 
to inﬂ uence either the hypogastric or pelvic afferents. Data supporting this theory 
have been presented in patients with a complete spinal cord lesion(41). The study 
demonstrated that the latencies of bladder neck responses during pudendal nerve 
stimulation increase signiﬁ cantly and are sensitive to a-blocking agent phentola-
mine, suggesting the involvement of sympathetic a-adrenergic ﬁ bres. Somatic af-
ferent pudendal nerve ﬁ bres project to sympathetic neurons in the thoracolumbar 
spinal cord and the sympathetic bladder neck outﬂ ow travels with the hypogastric 
nerve maintaining the bladder neck tone via a-adrenergic receptors(42-44).
Another suggested mechanism of action is that the sympathetic system is activa-
ted that suppresses bladder activity via the b-adrenergic system or spinal inter-
neurons that release inhibitory neurotransmitters such as enkephalin, glycine or 
g-aminobutyric acid(45).
Pudendal nerve stimulation in healthy volunteers showed speciﬁ c activation of 
the somatosensory and somatomotor cortex(46) on functional magnetic resonance 
imaging (fMRI). The ﬁ rst has been conﬁ rmed by several studies(47,48). Furthermore, 
it has been suggested that the amygdala and periaqueductal grey are activated 
during pudendal nerve stimulation(46). Pudendal nerve stimulation-induced cortical 
activation is, however, not identical to SNS-induced cortical activation. A larger 
similarity was expected as S2 and S3 roots contribute 60.5 and 35.5%, respectively, 
to the overall pudendal afferent activity(49). The activity of pudendal nerve stimula-
tion was, however, conﬁ ned to a single level (S2) in 18% and even to a single root 
in 8% of the participants. Therefore, direct pudendal nerve stimulation could be 
more effective as more afferents are stimulated than during SNS(6,50), as has been 
conﬁ rmed by Peters et al.(51•). To date, no results have been published of a compa-
rative study on cortical activation during SNS and pudendal nerve stimulation in 
patients with lower urinary tract dysfunction.
A carry-over effect has been shown in animal studies for pudendal nerve stimu-
lation(52) and intravesical stimulation(53), in contrast to SNS where up till now no 
carry-over effect has been described. For intravesical stimulation, the carry-over 
 effect is supposed to be caused by the long-term potentiation of excitatory synap-
ses in the central micturition reﬂ ex pathway(53), analogous as has been described 
for other central excitatory synapses(54). It has been suggested that the carry-over 
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effect of pudendal nerve stimulation could be caused by the negative modulation 
of excitatory synapses in the central micturition reﬂ ex pathway(52). This is suppor-
ted by the study of Bear and Malenka(55), which showed that intense activation of 
inhibitory input to target cells results in a prolonged decrease in synaptic efﬁ cacy 
of excitatory synapses (i.e. long-term depression) in the hippocampus. Long-term 
depression could be the mechanism of action for the carry-over effect as well 
for TENS and percutaneous tibial nerve stimulation (PTNS). Although a clear 
carry-over effect has not been described for both therapies in an animal model, it 
is to be expected as patients are successfully treated with intermittent therapy(56-
61).  The modulatory effect of pudendal nerve stimulation could be prolonged by 
frequent stimulation sessions(52), as the carry-over effect is reversible and patients 
are treated with frequent stimulation sessions during a certain period before their 
symptoms improve. This could be the case as well for TENS and PTNS; however, 
data supporting this assumption have not been presented yet.
Other suggested central modes of action for pudendal nerve stimulation are 
activation of tonic inhibitory mechanisms and shifts in ﬁ ring threshold of involved 
neurons(62).
The mechanism of action for TENS and PTNS in the treatment of overactive blad-
der syndrome is supposed to be a gate-control mechanism as well(25,30,63). It has, 
however, been demonstrated for TENS that different stimulation frequencies have 
different effects. TENS at 2 Hz is supposed to activate afferent pudendal nerve 
ﬁ bres and 50 Hz stimulation is considered to activate striated paraurethral muscle 
ﬁ bres(30,38). TENS at 150 Hz is supposed to inﬂ uence the anterior cutaneous branch 
of the iliohypogastric nerve or to inhibit the afferents of the pelvic splanchnic 
nerves that join the inferior hypogastric plexus, resulting in a decreased bladder 
contractility(56).
Another suggested mode of action for TENS is that it provides relief from pain, 
resulting in increased bladder ﬁ lling and postponed micturition(64). 
Tibial nerve stimulation, like SNS(65), reduces fos protein expression after chemi-
cal irritation of the bladder(66), indicating decrement of spinal neural cell activity 
and therefore, neuromodulative action. Fos protein is the third messenger that 
 modulates cell activity and is especially expressed in neurons after external stimu-
lation(66) and in the spinal cord after lower urinary tract irritation(67).
The tibial nerve is a mixed nerve containing sensory and motor nerve ﬁ bres. PTNS 
is supposed to treat overactive bladder syndrome by modulating  signals from and 
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towards the bladder via the sacral plexus by retrograde afferent stimulation(61). This 
has been conﬁ rmed by studies in anaesthetized female cats(68). The study has also 
conﬁ rmed the observation that the effect of PTNS is temporary and that main-
tenance treatment is necessary as PTNS reversibly modulates the micturition reﬂ ex 
in the female cat.
voiding disorders
Different theories on the mechanism of action have been proposed. Direct 
 afferent pudendal nerve stimulation resulting in a direct change of pelvic ﬂ oor 
behaviour(69), as well as a rebound phenomenon(70), suppression of the guarding 
reﬂ exes(3) and retuning of the L and M regions or ‘on–off’ switch mechanism in the 
brainstem(25), have been suggested.
The guarding reﬂ ex is a bladder-to-urethral reﬂ ex and is mediated by sympathetic 
afferent pathways to the urethra. The reﬂ ex is excitatory and results in contraction 
of the urethral smooth muscle during the storage phase of the bladder(71). The 
guarding reﬂ ex is activated during coughing or exercising resulting in momentarily 
increased bladder pressure, which prevents stress urinary incontinence by contrac-
tion of the external urethral sphincter. The reﬂ ex is activated as well by signalling 
of bladder afferents that synapse with sacral interneurons, which in turn activate 
efferent neurons of the external urethral sphincter(72). Animal studies have provi-
ded data indicating that the guarding reﬂ exes can be modulated by afferent nerve 
activation and inhibit bladder activity by spinal or supraspinal pathways (73-78).  
The retuning of the ‘on–off’ switch seems to be a more logical mechanism of 
action for neuromodulation, as nonobstructive bladder retention is supposed 
to be caused by a malfunction of the ‘on–off’ switch mechanism due to urethral 
sphincter and pelvic ﬂ oor spasticity(79). Evidence supporting this theory has been 
provided by PET studies, which showed pontine activation during SNS in patients 
with urinary retention(80). Contradicting data have been presented as well.  Single 
photon emission tomography (SPET) during SNS showed an increase in the regio-
nal cerebral blood ﬂ ow of all brain areas which are activated during micturition(81). 
This study was, however, performed in healthy volunteers and not in patients with 
nonobstructive voiding dysfunction.
Retuning of the ‘on–off’ switch could be the mechanism of action as well for 
PTNS. Up till now, no data, however, have been presented that conﬁ rm this 
 assumption.
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According to Vapnek and Schmidt(82), SNS treats nonobstructive retention by eli-
minating the spasticity of the urethral sphincter and pelvic ﬂ oor and not by direct 
activation of the parasympathetic sacral nerves, as the stimulation intensity of SNS 
is too low for the depolarization of these unmyelinated nerve ﬁ bres.
conclusions
Although many hypotheses have been given and much research has been perfor-
med, the exact mechanism of action of neuromodulation in the treatment of lower 
urinary tract dysfunction is still unclear. In the treatment of stress incontinence, it 
seems likely that neuromodulation induces physiological changes in the sphincter 
muscles and pelvic ﬂ oor. In the treatment of overactive bladder syndrome, non-
obstructive voiding dysfunction and chronic pelvic pain, the mechanism of action 
seems to be more complicated. The mechanism is most likely a combination of 
the different suggested modes of action, involving the neuroaxis at different levels.
abbreviations
PET photon emission tomography
PTNS percutaneous tibial nerve stimulation
SNS sacral nerve stimulation
TENS transcutaneous electrical nerve stimulation
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abstract
Objectives 
Tibial nerve stimulation was performed to modulate the micturition reﬂ ex in 
anaesthetized female cats. 
Methods
Baseline micturition reﬂ ex volume (MRV) was determined in 7 cats by cystometry. 
Subsequently MRV was determined during continuous tibial nerve stimulation 
(10 Hz, 100 microsec., mean 2 mA (range 1-4)). Afterwards, cystometries were 
repeated until baseline values were reached. In 2 cats that responded positively 
on tibial nerve stimulation (i.e. an increased MRV during tibial nerve stimulation), 
MRV was also determined during median nerve stimulation (10 Hz, 100 microsec., 
mean 2 (range 1-2 )).
Results
In only 5 cats the reﬂ ex was present, with a mean baseline MRV of 54 mL (SD 26). 
During tibial nerve stimulation mean MRV signiﬁ cantly increased to 71 mL (SD 30, 
p< 0.001).  Afterwards, MRV returned to mean 54 mL (SD 27, p< 0.002). In 1 cat a 
carry-over effect of 103 minutes was found. During tibial and median nerve stimu-
lation no increment in heart rate and blood pressure, nor paw retraction occurred. 
Median nerve stimulation had no effect on MRV.
Conclusions
The cat model is suitable to investigate the effect of tibial nerve stimulation on 
the micturition reﬂ ex. It was demonstrated that tibial nerve stimulation reversibly 
modulates the micturition reﬂ ex in anaesthetized female cats.
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introduction
Overactive bladder syndrome (OAB dry and wet) is a common urological problem 
that can strongly affect patients’ quality of life(1). In most cases the aetiology is 
unknown and symptoms are difﬁ cult to treat. If conservative treatment (i.e. beha-
vioral techniques, physiotherapy or pharmacotherapy) fails, patients can be treated 
with surgery such as bladder distension, augmentation or replacement. Surgical 
treatment, however, has major drawbacks such as irreversibility, and high recur-
rence as well as complication rates(2).  
Percutaneous tibial nerve stimulation (PTNS) has been introduced as an alterna-
tive treatment for patients with refractory OAB who are not ready or ﬁ t for surgical 
treatment(2). Signiﬁ cant changes in quality of life and parameters on both bladder 
diaries and urodynamic evaluations have been described in observational 
studies(2-5).  Up till now it has not irrefutably been proven that PTNS is more than a 
placebo effect. A randomized double-blinded placebo-controlled trial to investigate 
the efﬁ cacy of PTNS in patients with refractory OAB wet is underway but results 
are not available yet. In addition animal experiments are needed to shed some 
light on this matter. 
The feline animal model is a frequently used model for studying the modulative 
effect of neuromodulation on the bladder function(6-9).  It has been demonstrated 
in these animal studies that both afferent pudendal nerve stimulation and afferent 
sacral nerve stimulation can inhibit the micturition reﬂ ex. There are very strong 
indications that at brainstem and diencephalic level micturition is organized in the 
same way in cats and humans(10), which makes it tempting to extrapolate results. 
For tibial nerve stimulation contradicting data have been presented, concerning 
the effectivity of micturition reﬂ ex inhibition in cats(9,11). However, tibial nerve 
stimulation proved to be effective in primates(12). The present study was designed 
to investigate whether tibial nerve stimulation can inhibit to micturition reﬂ ex in 
anaesthetized female cats. 
materials and methods
The present study was carried out after approval of the local review board. Between 
October 2003 and December 2004, 7 female cats (mean weight 3.2 kg, range 
2,5-4) were used for this research. Before the study was performed a pilot study 
was undertaken in 3 female cats (mean weight 3.7 kg, range 3,5-4) to determine the 
best anaesthesia protocol. All animals were housed at the Central Animal Labora-
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tory. Tap water and standard cat chow were freely available, except 24 hours before 
the study was performed.  No control group was used in this study, since the 
individual cats were their own controls. The protocol was performed twice in the 
same animal. Between two sessions was a period of one week. The animals were 
euthanized at the end of the experiment by penthotal, either by an injection in the 
heart or intravenously.
The primary objective of the study was deﬁ ned as a signiﬁ cant increase of volume 
at which the micturition reﬂ ex occurs (micturition reﬂ ex volume, MRV) during 
tibial nerve stimulation. 
Induction of the cats
7 female cats were anaesthetised with ketamine (10 mg/kg/hour i.v.) and xylazine 
(2 mg/kg/hour i.v.).  A foreleg vein was cannulated for anaesthesia and ﬂ uid injec-
tions (6-10 mL/hour), for which an infusion pump was used. The infusion rate was 
continuous and was not altered in any of the cats during the study. The internal 
carotid artery was cannulated for blood pressure recordings. A pulse oxy meter
monitored the heart rate and O2 saturation. The temperature was kept at 38-39 °C 
by a heating lamp and mattress. After zero set, a 6 Fr double-lumen micro-tip 
catheter (MMS, Enschede, the Netherlands) was inserted transurethrally into the 
bladder and ﬁ xated with a ligature. Both lumens of the catheter were separately 
connected to an infusion pump and a pressure transducer. After zero set, a 
6 Fr single-lumen micro-tip catheter (MMS, Enschede, the Netherlands) was 
inserted into the anal canal and a pressure transducer. The pressure signals were 
displayed and stored on an urodynamic unit and on a digital chart recorder for off 
line analysis. The voided urine was collected in a bowl.
Cystometry in anaesthetized cats
After adequate anaesthesia and analgesic depth were reached (i.e. the eyelash 
reﬂ ex was almost absent and absence of paw retraction on moderate pinching), 
baseline micturition reﬂ ex volume (i.e. MRV) was determined by ﬁ lling the blad-
der with body warm saline at a constant infusion ﬂ ow of 1,0 mL/minute. When 
the micturition reﬂ ex occurred, the infusion was stopped immediately and the 
bladder was evacuated through the catheter. MRV was determined by measuring 
the collected voided and catheterized residual volume. This was repeated 2 times. 
Between cystometries there was a resting period of 5 minutes. Electrical stimula-
tion was performed after a resting period of one hour. 
Electrical nerve stimulation
To determine the effect of tibial nerve stimulation on the micturition reﬂ ex volume, 
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an acupuncture needle was placed in the vicinity of the tibial nerve at 1-2 centi-
metres above the medial ankle in 1 leg and a second needle approximately 1 cm 
proximal to the ﬁ rst. Both needles were connected to a stimulator (Interstim®, 
Medtronic Inc., Minneapolis, Minnesota). Stimulation was performed continu-
ously during cystometry at 10 Hz, 100 microseconds and at amplitude above the 
motor response threshold, which did not result in an increment in heart rate and 
blood pressure(11). Stimulation was stopped when the micturition reﬂ ex occur-
red and MRV was determined as described above. Cystometry was then resumed 
and continued until MRV returned to baseline values. This was repeated at least 
once. Between stimulation sessions was a resting period of 5 minutes. In 2 cats, in 
which MRV was successfully modulated by tibial nerve stimulation (i.e. a marked 
increase of MRV), stimulation of the median nerve was performed, using the same 
parameters as for tibial nerve stimulation. In the vicinity of the median nerve, 
approximately 1-2 cm’s below the elbow joint, an acupuncture needle was placed 
and a second needle approximately 1 cm proximal to the ﬁ rst. Both needles were 
connected to the stimulator.
Data analysis
Data are expressed as the mean ± SD. The statistical analyses were performed 
with commercial software (SPSS version 10, Chicago, Illinois, USA). Comparison 
of the results at baseline, during PTNS and after PTNS were conducted with the 
Wilcoxon Signed Ranks Test.
results
Rhythmic bladder contractions were present during cystometry in all cats as 
described by Klevmark(13). These contractions usually occurred in higher frequency 
and amplitude with increased bladder ﬁ lling, resulting in a micturition reﬂ ex and 
voiding in 5 out of 7 cats. In 2 cats in whom no such reﬂ ex could be determined 
cystometry was performed until the bladder pressure had gradually increased with 
20 cmH2O or spontaneous urine loss without a recorded bladder contraction (i.e. 
overﬂ ow) occurred, after that the bladder was evacuated. If the micturition reﬂ ex 
had not occurred after 2-3 cystometries, saline at 4 °C was used. This was perfor-
med in all cats.  It took a mean of 4 hours (range 2-7,5) for the ﬁ rst micturition 
reﬂ ex to occur. In 3 cats the micturition reﬂ ex was absent during the ﬁ rst measu-
rement session but present during the second. Since according to the protocol all 
cats were euthanized after the second measurement session, data of only 
1 measurement session could be collected in these cats. The results in the indivi-
dual cats are presented in table 1.
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table 1   The micturition reﬂ ex volume (mL) at baseline, during and after tibial nerve stimula-
tion in 5 female cats and during median nerve stimulation in 2 cats.
 Micturition reﬂ ex volume (mL)
 Mean (SD)
  Baseline During tibial  After tibial During median
   nerve stimulation nerve stimulation  nerve stimulation
Cat 1  22 (1.2) 31 (1.4) 20 (3.5) -
Cat 2  47 (2.8) 55 (3.6) 46 (1.4) -
Cat 3  44 (12.3) 61 (7.1) 47 (12.0) -
Cat 4  102 (4.7) 116 (1.3) 101 (0.7) 97 (4.2)
Cat 5  56 (7.1) 63 (11.1) 54 (8.4) 55 (9.6)
Mean MRV at baseline was 54 mL (SD 26). Subsequently, tibial nerve stimulation 
(100 microsec., 10 Hz) was continuously performed during cystometry at a mean 
stimulation intensity of 2 mA (range 1-4). In all animals tibial nerve stimulation 
resulted in ﬂ exion of the toes. The stimulation amplitude was not adjusted during 
the measurement, since the motor response was continuously present. No paw 
retraction or increase in blood pressure and heart rate occurred during stimula-
tion. Stimulating at a higher intensity was painful, since it did result in retraction of 
the stimulated paw and a rise in both blood pressure and heart rate. During tibial 
nerve stimulation mean MRV signiﬁ cantly increased to 71 mL (SD 30, p< 0.001) 
and met the primary objective. The rhythmic bladder contractions seemed to occur 
at a larger volume and with lower amplitude, but not signiﬁ cantly. Moreover, the 
duration and maximal amplitude of the micturition reﬂ ex were not signiﬁ cantly 
altered by the stimulation. After tibial nerve stimulation mean MRV returned to a 
baseline value of 54 mL (SD 27, p< 0.002). Cystometries directly after the stimula-
tion showed that there was no carry-over effect, except in 1 cat. In animal number 3 
it took 103 minutes before MRV had returned to baseline values. 
The effects of tibial nerve stimulation on the micturition reﬂ ex in the female cat are 
shown in ﬁ gures 1 and 2.
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ﬁ gure 1  Baseline cystometry in cat number 1
The detrusor pressure (Pdet) is shown with the time registration (minutes) below. The micturition 
reﬂ ex occurs after 16 minutes with a micturition reﬂ ex volume of 17 mL.
ﬁ gure 2  Cystometry during PTNS in cat number 1
The detrusor pressure (Pdet) is shown with the time registration (in minutes) below. The micturi-
tion reﬂ ex occurs after 32 minutes with a micturition reﬂ ex volume of 32 mL.
In 2 cats, in which MRV was successfully modulated by tibial nerve stimulation 
(i.e. a marked increase of MRV), median nerve stimulation was performed (mean 
2 mA (range 1-2), 100 microsec., 10 Hz). Stimulation resulted in ﬂ exion of the toes 
of the foreleg and stimulation amplitude was not adjusted during the measure-
ment, since the motor response was continuously present. During stimulation 
of the median nerve no paw retraction or rise in blood pressure and hearth rate 
occurred. Median nerve stimulation had no effect on MRV.
discussion
The primary objective (i.e. a signiﬁ cant increase of MRV during tibial nerve stimu-
lation) was achieved in the present study, demonstrating that afferent tibial nerve 
stimulation suppresses and modulates the micturition reﬂ ex, as has been demon-
strated for pudendal nerve stimulation and sacral nerve stimulation(6-9).  This cor-
roborates the urodynamic data that have been presented on PTNS treated patients 
with refractory urge urinary incontinence(3,4). 
The present study demonstrates also that the feline animal model is useful to 
investigate the effects of neuromodulation techniques, since a micturition reﬂ ex 
could be observed and tibial nerve stimulation could be performed. However, the 
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use of this model is challenging, since the micturition reﬂ ex was present in 5 out 
of the 7 cats, in 3 cats the micturition reﬂ ex was only present during the second 
measurement and it took a mean of 4 hours (range 2-7,5) before the ﬁ rst reﬂ ex 
occurred. 
Female cats were used in this study since it was easier to insert a 6 Fr transurethral 
catheter into a female cat than in a male. Anaesthesia with kematine and xylazine 
has been used successfully before(11). The anaesthesia was continuous, since an 
infusion pump was used with a ﬁ xed infusion rate that was not altered during the 
measurement. Furthermore, the anaesthesia depth was checked at regular inter-
vals by testing the presence of the eyelash reﬂ ex. The reﬂ ex was almost absent and 
had not altered during the measurements. Therefore it is unlikely that the anaes-
thesia did inﬂ uence the results of the study and nor does it explain the observation 
that the micturition reﬂ ex was present in 5 out of 7 cats and that in 3 cats the reﬂ ex 
was only present in the second measurement. The use of saline for cystometry 
at 4 °C in stead of body temperature seemed not to inﬂ uence the occurance of 
the reﬂ ex either. Furthermore, there seemed to be no difference in the biometric 
parameters (blood pressure, heart rate, temperature, anaesthesia depth, analgesic 
depth) of the cats and all were acclimatized a week before the ﬁ rst measurement 
of the study was performed. 
The 5-minute resting period between the cystometries is short, since it is known 
from patient studies that repeated cystometries can inﬂ uence the results(14). How-
ever, the 5-minute resting period is similar to the resting period that has been used 
by Jiang and Lindstrom(7). Furthermore, the 5-minute resting period seemed not to 
inﬂ uence MRV in this study since the standard deviation in the individual cats is 
very small (table 1). Cat number 3 and 5 were the only cats that had a micturition 
reﬂ ex during both measurements. There was a difference between baseline MRV 
during the ﬁ rst and second measurement, resulting in a larger standard deviation. 
This could be explained by a varying urine production rate during the two sessions. 
The ureters were left intact, and therefore any urine produced during the study 
was collected in the bladder. The urine production did vary despite the continuous 
intravenous ﬂ uid injection. This did not inﬂ uence MRV, since it was determined by 
measuring the voided volume collected in a bowl, together with the catheterized 
residual volume.
It has been demonstrated in animal studies that the effect of afferent nerve stimu-
lation is reversible and that a carry-over effect is present. The ﬁ rst observation has 
been conﬁ rmed by our data, since the volume at which the micturition reﬂ ex occur-
red returned to baseline values after cessation of tibial nerve stimulation. This 
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conﬁ rms the notion that maintenance treatment is necessary in successfully trea-
ted patients(15). The second observation being that of a carry-over effect was only 
conﬁ rmed in 1 out of 5 cats. It was expected from our clinical data, since patients 
have been successfully treated with 12 weekly sessions(2,4,5). A distinct carry-over 
effect has been described after pudendal nerve stimulation, which was present in 
all cats(16). Moreover, it has been described in rats that it took more than an hour 
before the micturition reﬂ ex volume returned to baseline values(7). Nevertheless, a 
satisfying explanation for the absent carry-over effect in our experiment in 4 out of 
5 cats cannot be provided. 
The tibial nerve (L4-S3) is a mixed nerve that contains sensory and motor nerve 
bundles. The mechanism of action of PTNS is still unclear, but it is supposed to 
modulate the signals to and from the bladder (S2-S3) via the sacral plexus by affe-
rent stimulation(5).  This suggests neuromodulative action, as has been conﬁ rmed 
by Chang et al.(17). The present study indicates that the sacral plexus is involved in 
modulating the micturition reﬂ ex by stimulation of the tibial nerve (L4-S3), since 
median nerve stimulation (C6-C8) did not change the micturition reﬂ ex volume 
in the anaesthetized female cat model. Further research is needed to investigate 
whether for instance increased sympathetic activity is involved in the mechanism 
of action, or suprasacral (i.e. pontine and/or cortical) areas as has been suggested 
in the literature(18,19).  
conclusions
This anaesthetized cat model is useful to investigate the effect of tibial nerve 
stimulation. It was demonstrated that tibial nerve stimulation reversibly modulates 
the micturition reﬂ ex and increases the volume at which the reﬂ ex occurs. 
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abstract
Objectives
It is assumed that improvement of voiding variables will lead to improved quality 
of life in patients with lower urinary tract dysfunction. The present study was per-
formed to investigate the relationship between quality of life and voiding variables 
in percutaneous tibial nerve stimulation (PTNS) treated patients.
Methods
30 patients with urge urinary incontinence were treated with PTNS. 24-hour blad-
der diaries and quality of life questionnaires (SF-36 and I-QoL) were ﬁ lled out at 
baseline and after PTNS. 
Results
A signiﬁ cant correlation (p<0.05) was present between number of used pads and 
SF-36 domains physical and vitality, between number of incontinence episodes and 
SF-36 domains physical and role physical, between nocturia and SF-36 domains 
general and mental health, between mean voided volume and the SF-36 domain 
role physical and ﬁ nally, between mean voided volume and the I-QoL score.
Conclusions
PTNS has a useful place in the treatment of refractory urge Incontinence and 
should at least be considered as a therapeutic alternative before turning to aggres-
sive surgery, since voiding and quality of life variables do signiﬁ cantly and quanti-
ﬁ ably correlate in PTNS treated patients with refractory urge urinary incontinence. 
Patients must have a reduction of at least 2 used pads before their quality of life 
improves. This could be the best deﬁ nition of successful therapy for patients with 
urge urinary incontinence. 
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introduction
Percutaneous tibial nerve stimulation (PTNS) has been used to treat patients with 
complaints of lower urinary tract dysfunction, since its introduction in 1999(1). 
Moreover, PTNS has been presented as an alternative treatment for refractory non-
neurogenic patients who are not ready for surgical treatment(2). 
Signiﬁ cant improvements documented on bladder diary, quality of life question-
naires and urodynamic evaluations have been reported(2-8). It is generally assumed 
that improved voiding variables will lead to improved quality of life(9). However, the 
correlation between these variables has not been investigated. The present study 
was performed to quantify the correlation between voiding variables and quality of 
life in PTNS treated patients with refractory urge urinary incontinence. 
patients and methods
Between November 2002 and January 2004, 4 male and 26 female patients were 
enrolled in a clinical trial. No control group was used for the present study. The 
use of a delayed implant group(10) was not possible, since an implantable  device 
was not available when the present study was carried out. All patients were 
 evaluated at the urology outpatients clinic for refractory urge urinary incontinence 
by history, physical and urological examination, including urodynamic evaluation 
and 24-hour bladder diaries(11-13). Methods, units and deﬁ nitions used in this study 
conform to the standards recommended by the International Continence  Society 
(ICS)(14), except for the 24-hour bladder diaries(15). Data suggesting that such 
 diaries are sufﬁ cient to evaluate the patients’ micturition complaints have been 
presented(11-13). Moreover, 24-hour bladder diaries have been used previously(2,5,7).
Since there is no ICS deﬁ nition of urge urinary incontinence that is based on the 
outcome of bladder diaries, we deﬁ ned urge urinary incontinence as urgency 
 leading to urinary leakage occurring at least 3 times per 24 hours on bladder diary. 
All medication that could inﬂ uence bladder function was stopped at least 2 weeks 
before treatment or continued without dose changes during the entire study. 
 Speciﬁ c exclusion criteria as described by van Balken et al. were used(2). 
30 patients with a mean age of 51 years (range 20-72) were treated for complaints 
of urge urinary incontinence. The patients had complaints for a mean period of 
10 years (range 1-28). All were treated with conservative therapy without result. 
28 patients were unsuccessfully treated with oral medication. Patients had had 
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a mean of 2.2 (range 0-8) prescriptions for their complaints; anticholinergics, 
(oxybutynin, tolterodine, ﬂ avoxate hydrochloride), alpha-blockers, antidepressants, 
antibiotics, oestrogens and desmopressin were prescribed mostly. 14 patients were 
treated with physiotherapy or bladder training, 7 with the test stimulation phase of 
sacral nerve stimulation and 6 with other treatments, all without success. 
13 patients had had unsuccessful surgical treatment (range 0-2 operations). These 
surgical therapies included colposuspension, urethra dilatation, urethrotomy, 
bladder distension with or without bladder biopsies, intravesical Botulinum toxin 
injections, bulk injections, and transurethral resection of the prostate.
PTNS was performed as described by van Balken et al.(2). A low-voltage (9 V) 
stimulator (Urgent-PC®, CystoMedix Inc., Anoka, MN, USA) was used. The 
stimulator has an adjustable stimulation intensity of 0-10 mA and ﬁ xed stimula-
tion parameters: pulse width 200 microseconds, and pulse rate frequency 20 Hz.  
The amplitude was slowly increased until ﬂ exion of the big toe and/or fanning of 
the other toes occurred, to conﬁ rm correct placement of the needle. If the motor 
response did not occur, the needle placement procedure was repeated. All patients 
had a sensory response to the stimulation, i.e. a radiating sensation under the 
sole of the foot and/or in the toes. Ongoing stimulation at the intensity of the 
motor response was too painful for nearly all patients, so the current was set at a 
well-tolerable level resulting in the sensory response. If the patients adapted to the 
stimulation the intensity was adjusted. Patients were treated with 30-minute ses-
sions 3 times a week during a period of 4 weeks. PTNS was performed on Monday, 
Wednesday and Friday of each week. 
At baseline patients were evaluated by having them ﬁ ll out a 24-hour bladder diary, 
as well as general and disease speciﬁ c quality of life questionnaires. This proce-
dure was repeated after PTNS treatment. In the bladder diaries the micturition 
frequency, voided volume (cc), number of incontinence episodes, and the number 
of pads were recorded. General and disease speciﬁ c quality of life questionnaires 
were evaluated with the 36-item short-form health survey (SF-36)(16) and the incon-
tinence-speciﬁ c quality of life assessment (I-QoL)(17). The SF-36 consists of 
36 items regarding distinct health status concepts. The speciﬁ c domains are 
physical health, role physical, role emotional, social function, pain, mental health, 
vitality and general health. The maximum score for each domain is 100, and higher 
scores relate to better quality of life. The I-QoL questionnaire consists of 22 items, 
each with a 5-point response scale. As with the SF-36 questionnaire a high score 
means a good quality of life. 
Changes in the voiding and quality of life variables after treatment were tested on 
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statistical signiﬁ cance using the Wilcoxon Signed Ranks Test. Correlation between 
change in voiding and quality of life variables were statistically tested on signiﬁ can-
ce using the Spearman’s Correlation Test. The statistical analysis was performed 
using commercial software (SPSS version 10, Chicago, Illinois, USA).
results
Of the 30 included patients 29 could be evaluated. One patient did not complete 
follow up. Patients were treated with a mean pulse intensity of 3.2 mA (range 1.0-
6.5). Complications of the therapy – minor bleeding or a temporary painful/numb 
feeling at the insertion site or under the sole of the foot – occurred rarely. 
After PTNS, 4 out of the 5 voiding variables changed signiﬁ cantly on bladder diary 
compared to baseline (table 1). Concomitantly, 5 out of the 8 domains of the SF-36 
questionnaire changed signiﬁ cantly, as well as the I-QoL score (table 2). Signiﬁ cant 
correlations could be detected between voiding and quality of life variables (table 
3). A reduction of number of used pads did correlate with an increase in the SF-36 
domain physical function. Results of linear regression suggested that a reduction 
of 1 used pad would result in a 5-point increase of the physical function domain 
of the SF-36 questionnaire (ﬁ gure 1a).  Furthermore, a reduction of number of 
used pads did correlate with an increase in the SF-36 domain vitality. Results of 
linear regression suggested that a reduction of 1 used pad would result in a 3-point 
increase of the physical function domain of the SF-36 questionnaire (ﬁ gure 1b).  
No other suggestions of linear regression between voiding variables and SF-36 
domains were found. 
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table 1  Voiding variables and QoL scores at baseline and after PTNS in 29 patients
Variable Mean (SD) at baseline Mean (95% CI) change p
Voiding   
 Number of voids 13.0 (6.5) -1.3 (-2.7, +0.1) 0.070
 Nocturia 2.2 (1.5) -0.8 (-1.3, -0.2) < 0.01
 Mean voided volume (mL) 128.6 (55.4) +51.8 (+17.0, +86.5) < 0.01
 Number of incontinence episodes 8.0 (7.7) -4.1 (-6.2, -2.0) < 0.01
 Number of used pads 3.9 (3.6) -1.3 (-2.3, -0.4) < 0.01
QoL   
SF-36 domains:   
 Physical 66.0 (24.9) +10.0 (+0.6, +19.4) < 0.05
 Role physical 49.1 (47.4) +19.8 (+2.9, +36.8) < 0.05
 Role emotional 62.1 (46.9) +21.8 (+4.5, +39.2) < 0.05
 Social function 57.8 (28.6) +12.0 (+1.0, +23.0) < 0.05
 Pain 62.5 (25.5) +10.5 (+4.5, +16.5) < 0.01
 Mental health 66.3 (14.9) -3.2 (-10.6, +4.1) 0.375
 Vitality 53.4 (21.5) +2.8 (-3.7, +9,2) 0.386
 General health 56.9 (25.4) +4.6 (-1.4, +10.7) 0.128
   
I-QoL 61.0 (17.4) +11.8 (+4.5, +19.1) < 0.01
table 2   Correlation between changes in voiding and quality of life variables in 
29 patients
 Physical Role  Role  Social  Pain Mental  Vitality General 
  physical emotional function  health  health
Void1 -0.21 0.06 0.10 0.06 -0.21 -0.27 -0.16 -0.02
Mvv2 0.19 0.37* 0.21 0.14 0.11 0.20 0.34 -0.02
Noct3 -0.24 -0.08 -0.26 -0.28 -0.21 -0.43* -0.34 -0.39*
Inco4 -0.39* -0.54* -0.28 -0.32 -0.11 -0.08 -0.35 -0.15
Pad5 -0.46* -0.08 -0.26 -0.34 -0.11 0.07 -0.44* 0.02
*p < 0.05, 1number of voids, 2mean voided volume (mL), 3nocturia, 4number of incontinence 
episodes, 5number of used pads
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ﬁ gure 1   Linear regressions between voiding and QoL variables in 29  patients treated with 
PTNS
ﬁ gure 1a
   Change in number of used pads
Linear regression coefﬁ cient -4,91 (Standard Error 1.68), R square 0.24, p<0.01
ﬁ gure 1b
   Change in number of used pads
Linear regression coefﬁ cient -3,29 (Standard Error 1.16), R square 0.23, p<0.01
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The I-QoL score did also signiﬁ cantly correlate with the voiding parameter mean 
voided volume. Results of linear regression suggested that a 100 cc increase of 
mean voided volume should result in a 10-point increase of the I-QoL score.  
discussion
Concerning the primary objective, a quantiﬁ able correlation between voiding and 
quality of life variables could be determined at baseline (data not shown). This 
conﬁ rms data presented by O’Conor et al.(9).  However, in the O’Conor study the 
effect of treatment on the quality of life was not investigated, nor was the cor-
relation between the change in quality of life and voiding variables. Moreover, the 
results at baseline conﬁ rm the statement that overactive bladder syndrome can 
strongly affect the patient’s quality of life(18). At baseline, the quality of life of the 
patient population was very poor compared to the national Dutch values of healthy 
persons (i.e. a difference of at least 10 points in all SF-36 domains), even compa-
red to patients with migraine(19). Various authors have conﬁ rmed the poor quality 
of life in patients with overactive bladder syndrome(9,20), indicating the necessity of 
treatment.
The present study has demonstrated that PTNS has an effect on the patient’s 
quality of life. A signiﬁ cant correlation has been demonstrated between number 
of used pads and the SF-36 domains physical and vitality, between mean voided 
volume and the SF-36 domain role physical, between number of incontinence 
episodes and the SF-36 domains physical and role physical, between nocturia and 
SF-36 domains mental health and general health and ﬁ nally between mean voided 
volume and the I-QoL score. This conﬁ rms the assumption that improvement of 
the voiding variables results in an improved quality of life(9). 
It was not possible in the present study to determine whether the effect that PTNS 
had on the patient’s quality of life was placebo or therapy induced.  This will be 
investigated in a designed randomized double-blinded placebo-controlled trial, 
which is being conducted. However, no data are available yet.
Up till now different deﬁ nitions of successful PTNS treatment have been used by 
various authors(3,4,7), which makes it difﬁ cult to compare the studies with each 
other. All deﬁ nitions were based on the clinical outcome on bladder diaries. The 
present study has demonstrated that PTNS has an effect on the patient’s quality of 
life. Therefore, a deﬁ nition of successful treatment based on quality of life impro-
vement would be more appropriate. The I-QoL quality of life questionnaire seems 
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not suited for the efﬁ cacy evaluation, since the I-QoL score only correlated with the 
voiding parameter mean voided volume. The SF-36 quality of life questionnaire is 
suited, since several domains did correlate with various voiding variables (table 3). 
According to Norman et al.(21) the threshold of discrimination for changes in 
health-related quality of life for chronic diseases appears to be approximately half a 
standard deviation. Extrapolating this to PTNS treated patients, the SF-36 domains 
should change approximately half a standard deviation SD at baseline before 
a change in quality of life is detected. In the present study similar results were 
described for all signiﬁ cant changes (table 2). Because of this we have set the cut 
off value for successful treatment at a minimal increase of 10 point in the SF-36 
domains physical and/or pain. The corresponding voiding parameter is number 
of used pads, which has a signiﬁ cant (p<0.01) linear regression coefﬁ cient of -4.91 
(Standard Error 1.68). Therefore, in order to detect a quality of life improvement 
and to be successfully treated, patients must have a decrease of at least 2 used 
pads.
conclusions
PTNS has a useful place in the treatment of refractory urge incontinence and 
should at least be considered as a therapeutic alternative before turning to aggres-
sive surgery, since there is a quantiﬁ able correlation between voiding and quality 
of life variables in PTNS treated patients with refractory urge urinary incontinence. 
The best deﬁ nition of successful PTNS therapy based on quality of life improve-
ment for patients with urge urinary incontinence is a reduction of at least 2 used 
pads on bladder diary.
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abstract
Objectives
To determine the effect of pausing percutaneous tibial nerve stimulation (PTNS) in 
successfully treated patients and the reproducibility of successful treatment. 
Methods
11 patients (mean age 51 years) with refractory overactive bladder syndrome (> 7 
voids and/or > 3 urge incontinence episodes per day) were successfully treated 
with PTNS and continued treatment. Patients ﬁ lled out bladder diaries and quality 
of life questionnaires (SF-36 and I-QoL) before (T1) and after a 6-week pause (T2) 
of maintenance PTNS and again after re-treatment (T3). The ﬁ rst objective was de-
ﬁ ned as a > 50% increase of the number of incontinence episodes and/or micturi-
tion frequency on bladder diary after the 6-week pause of maintenance PTNS. The 
second objective was deﬁ ned as a > 50% reduction of the number of incontinence 
episodes and/or micturition frequency on bladder diary after re-treatment.
Results
At T2, 7/11 patients (64%) had a > 50% increase of the number of incontinence 
episodes and/or micturition frequency on bladder diary after the 6-week pause 
of maintenance PTNS. Mean voided volume, nocturia, number of incontinence 
episodes and incontinence severity had signiﬁ cantly (p<0.05) deteriorated. At T3, 
9/11 patients (82%) had a > 50% reduction of the number of incontinence episo-
des and/or micturition frequency on bladder diary after re-treatment. Nocturia, 
number of incontinence episodes, incontinence severity, mean voided volume and 
quality of life had signiﬁ cantly (p<0.05) improved.
Conclusions
Continuous therapy is a necessity in successfully PTNS treated patients. The 
 efﬁ cacy of PTNS can be reproduced in formerly successfully treated patients.
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introduction
Percutaneous tibial nerve stimulation (PTNS) is an alternative therapy for refrac-
tory non-neurogenic lower urinary tract dysfunction(1). After successful treatment 
patients are put on maintenance therapy(2). So far there have been no reports 
on long-term results in treatment of patients with overactive bladder syndrome 
(OAB), nor are any data available on the effect of prolonged interruption of the 
maintenance treatment, nor concerning the question if the efﬁ cacy of the therapy 
can be reproduced. 
The present study was performed to evaluate the effect of prolonged interruption 
of the maintenance therapy on the complaints of patients with overactive bladder 
syndrome. A second goal was to investigate whether the efﬁ cacy of the therapy can 
be reproduced. 
patients and methods
Between November 2003 and January 2004, 11 patients were enrolled in a clini-
cal trial. Patients were evaluated at the outpatients’ clinic for overactive bladder 
syndrome (OAB) by history and physical and urological examination, including 
urodynamic evaluation. Methods, units and deﬁ nitions used in this study meet 
the standard recommended by the International Continence Society(6), except for 
the 24-hour bladder diaries(7). These bladder diaries are sufﬁ cient to evaluate the 
patients’ micturition complaints(3-5). 
OAB was deﬁ ned as more than 7 voids per day and/or a sudden insuppressibly 
urge to void, culminating in urinary leakage at least 3 times per day on bladder 
diary. All medication that could inﬂ uence bladder function was stopped at least 
2 weeks before treatment or continued without dosage changes during the entire 
study. Speciﬁ c exclusion criteria for PTNS as described by van Balken et al. were 
used(1) (table 1). 
All patients, 5 men and 6 women with a mean age of 51 years (range 33-66), were 
diagnosed with OAB (2 patients had urgency/frequency syndrome and 9 had 
urge urinary incontinence). All patients were refractory to conservative treatment. 
Oral medication was unsuccessful in all and patients had had mean 3 prescrip-
tions (range 1-8) for their complaints. Mostly anticholinergics, alpha-blockers, 
anti depressants, antibiotics, and desmopressin were prescribed. 6 patients were 
treated with physiotherapy or bladder training, 5 with sacral nerve stimulation and 
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4 with other therapies, all unsuccessfully. 4 patients had had unsuccessful surgical 
treatment (range 1-2 operations). The performed surgical therapies were colposus-
pension, urethra dilatation, bladder distension, bulk injections and transurethral 
resection of the prostate.
All patients were prioryly successfully treated with PTNS (> 50% reduction of 
incontinence episodes and/or micturition frequency on bladder diary) and had 
continued treatment. 5 patients had maintenance PTNS in an outpatients’ setting, 
and all were diagnosed with urge urinary incontinence.  6 patients performed 
self-administered home treatment, either by transcutaneous stimulation with 2 
surface electrodes (5 patients) or percutaneous tibial nerve stimulation (1 patient). 
Of these patients 4 were diagnosed with urge urinary incontinence and 2 patients 
with urgency/frequency syndrome. Maintenance therapy was performed during a 
mean period of 13 months (range 1-36 months). 
table 1  Exclusion criteria
Exclusion criteria
Younger than 18 years
Symptoms existing for less than 6 months
Pregnancy or intention to become pregnant during the course of the study
Active urinary tract or recurrent urinary tract infection  (5 or more recurrent infections during the 
last 12 months), carcinoma in situ, bladder malignancy, interstitial cystitis
Bladder or kidney stone
Severe cardiopulmonary disease
Use of pentosan polysulfate sodium or bladder installations, including dimethyl sulfoxide, bacillus 
Calmette-Guerin, Chloropectin or heparin
Uncontrolled diabetes
Diabetes with peripheral nerve involvement
Neurological disease like multiple sclerosis, Parkinson’s disease, cerebrovascular accident, biﬁ d 
spine or spinal cord lesion
Physiotherapy during the study
Bladder outlet obstruction (Abrams-Grifﬁ ths nomogram)
Transurethral instrumentation 4 weeks or less before or during the study
All patients paused maintenance PTNS for a 6-week period, and were re-treated 
after this period in outpatients’ setting. PTNS was performed as described by van 
Balken et al.(1). A low-voltage (9V) stimulator (Urgent-PC®, CystoMedix Inc, Anoka, 
MN, USA) was used. The stimulator had an adjustable stimulation intensity 
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0-10 mA and ﬁ xed stimulation parameters: pulse width 200 microseconds, pulse 
rate 20 Hz.  All patients had a sensory response to the stimulation: a radiating 
sensation at the sole of the foot and in the toes. Stimulation at the intensity of the 
motor response was too painful for almost all patients, so the current was set at a 
well-tolerable level resulting in the sensory response. If patients had adapted to the 
stimulation the current was adjusted, usually as soon as the sensation faded away. 
Patients were treated with 30-minute treatment sessions 3 times a week during a 
4-week period. PTNS was performed on Monday, Wednesday and Friday of each 
week.
At baseline (before the 6-week pause of maintenance PTNS, T1) patients were 
evaluated by 24-hour bladder diaries, as well as general (36-item short-form health 
survey, SF-36)(8) and disease speciﬁ c quality of life (incontinence-speciﬁ c quality of 
life assessment, I-QoL) questionnaires(9). This procedure was repeated after the 
6-week pause (T2), and after PTNS re-treatment (T3). In the bladder diary mictu-
rition frequency, voided volume (cc), number of incontinence episodes, severity 
of urine loss and the number of used pads were recorded. The severity of urine 
loss was described on a scale of 0-3 (i.e. 0– no urine loss, 1– loss of some drops, 
2– loss of small amount and 3– change of clothes due to urine loss). 
The ﬁ rst objective was deﬁ ned as a >50% increase of the number of incontinence 
episodes and/or number of voids on bladder diary after the 6-week interruption 
of the maintenance PTNS. The second objective was deﬁ ned as a >50% reduc-
tion of the number of incontinence episodes and/or number of voids on bladder 
diary after PTNS re-treatment. Comparison of the results before and after pausing 
maintenance PTNS and re-treatment were conducted with the Wilcoxon signed 
Ranks Test; the statistical analysis was performed with commercial software (SPSS 
version 10, Chicago, IL, USA).
results
At T1 (before the 6-week interruption of maintenance PTNS), the patients who 
performed self-administered home treatment (i.e. self-treatment group, 6 patients) 
tended to have lesser voiding parameters and quality of life compared to the pa-
tients who received maintenance treatment in an outpatient setting (i.e. outpatient 
group, 5 patients) (table 2 and 3). However statistical signiﬁ cance could not be 
determinated since the patient groups were too small.
At T2 (after 6-week pause of maintenance PTNS) 7 out of the 11 patients (64%) 
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met the ﬁ rst objective and had > 50% increase of the number of incontinence 
episodes and/or number of voids on bladder diary. 2 patients, who performed 
self-administered home treatment, had a deterioration of their symptoms but did 
not meet the ﬁ rst objective and 2 patients had no change of their symptoms on 
bladder diary, of which 1 performed self-treatment and another had maintenance 
treatment in an outpatient setting. All patients experienced a subjective deteriora-
tion of their symptoms. There was an objective signiﬁ cant deterioration (p<0.05) 
of nocturia, mean voided volume, and number of incontinences episodes and the 
SF-36 domain pain (table 2 and 3). 
The self-treatment group tended to still have slightly lesser voiding and quality of 
life parameters, compared to the outpatient group. However, statistical signiﬁ can-
ce could again not be determinated due to the small patient groups.
During PTNS a mean pulse intensity of 3.8 mA (range 1.6-7.8) was used. Compli-
cations of the therapy – minor bleeding or a temporary painful/numb feeling at the 
insertion site or under the sole of the foot – rarely occurred. 
At T3 (after PTNS re-treatment) 9 out of the 11 patients (82%)met the second ob-
jective and had a > 50% reduction of the number of incontinence episodes and/or 
number of voids on bladder diary. 2 patients had no improvement on bladder 
diary, of which 1 patient performed self-treatment and another had maintenance 
PTNS in an outpatient setting. 8 patients (73%) did again subjectively improve and 
wanted to continue the treatment. There was a signiﬁ cant (p<0.05) improvement 
of nocturia, mean voided volume, number of incontinence episodes, incontinence 
severity, I-QoL score and the SF-36 domains physical, role emotional, social func-
tion, pain and mental health (table 2 and 3). 
At T3 (after PTNS re-treatment) the difference with the data at T1 (before the 
6-week interruption) tended to be the largest in the self-treatment group. Again 
statistical signiﬁ cance could not be determinated due to the small patient groups.
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table 2  Voiding parameters at T1 to T3 in 11 patients
Parameters per 24 hours   Mean (SD) 
  T1• T2•• T3•••
Number of voids   
 Home1 12.5 (7.3) 13.0 (8.3) 8.5 (1.9)
 Clinic2 9.2 (2.9) 10.8 (4.1) 10.0 (3.9)
 All patients 11.0 (5.8) 12.0 (6.5) 9.2 (2.9)
Nocturia   
 Home1 1.7 (1.4) 3.7 (4.2) 0.7 (0.5)
 Clinic2 1.0 (0.7) 2.2 (1.3) 0.6 (0.9)
 All patients 1.4 (1.1) 3.0 (3.2)* 0.6 (0.7)*
Mean voided volume (mL)   
 Home1 190.3 (123.3) 95.8 (62.0) 222.0 (124.2)
 Clinic2 174.0 (60.1) 121.6 (37.1) 146.0 (45.4)
 All patients 182.9 (95.5) 107.6 (51.5)* 187.5 (100.6)*
Number of incontinence episodes   
 Home1 1.3 (2.4) 3.5 (4.5) 1.0 (1.5)
 Clinic2 2.6 (2.7) 12.0 (16.8) 5.6 (6.4)
 All patients 1.9 (2.5) 7.4 (12.0)* 3.1 (4.9)*
Incontinence severity3   
 Home1 0.3 (0.5) 1.2 (1.2) 0.8 (0.5)
 Clinic2 1.0 (0.7) 1.4 (0.5) 0.6 (0.5)
 All patients 0.6 (0.7) 1.3 (0.9) 0.6 (0.5)*
Number of used pads   
 Home1 1.5 (2.0) 2.2 (2.9) 0.7 (1.5)
 Clinic2 2.0 (1.0) 3.6 (2.4) 2.6 (1.5)
 All patients 1.7 (1.6) 2.8 (2.6) 1.6 (1.5)*
•Baseline, ••After 6-week pause of maintenance PTNS, •••After PTNS-retreatment, *p<0.05, 
16 patients who performed self-administered maintenance PTNS at home, 25 patients who had 
maintenance PTNS in an outpatient setting, 30= no urine loss, 1= loss of some drops, 2= loss of 
small amount and 3= change of clothes due to urine loss
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table 3  Quality of life parameters at T1 to T3 in 11 patients
Parameters per 24 hours   Mean (SD) 
  T1• T2•• T3•••
SF-36 domains
Physical   
 Home1 80.8 (16.9) 75.8 (28.4) 96.7 (4.1)
   Clinic2 79.0 (21.0) 70.0 (22.1) 81.0 (19.5)
   All patients 80.0 (5.4) 73.2 (7.4) 89.5 (4.5)*
Role physical   
   Home1 62.5 (49.4) 45.8 (51.0) 95.8 (10.2)
   Clinic2 55.0 (51.2) 55.0 (51.2) 70.0 (44.7)
   All patients 59.1 (14.4) 50.0 (14.7) 84.1 (9.7)
Role emotional   
   Home1 94.5 (13.6) 61.1 (39.0) 94.5 (13.6)
   Clinic2 73.3 (43.5) 66.8 (40.8) 93.3 (14.9)
   All patients 84.9 (9.4) 63.6 (11.4) 93.9 (4.1)*
Social function   
   Home1 66.7 (20.4) 58.3 (30.3) 81.3 (19.0)
   Clinic2 75.0 (23.4) 50.0 (15.3) 80.0 (14.3)
   All patients 70.5 (6.4) 54.5 (7.2) 80.7 (4.9)*
Pain   
   Home1 79.5 (27.9) 64.3 (30.7) 82.8 (18.8)
   Clinic2 73.4 (30.6) 51.2 (16.8) 75.0 (25.4)
   All patients 76.7 (8.4) 58.4 (7.6)* 79.3 (6.4)*
Mental health   
   Home1 61.3 (12.08) 58.0 (18.5) 72.0 (13.4)
   Clinic2 72.0 (17.2) 69.6 (16.4) 80.0 (14.7)
   All patients 66.2 (4.6) 63.3 (5.4) 75.6 (4.2)*
Vitality   
   Home1 60.0 (23.2) 46.7 (24.2) 67.5 (12.9)
   Clinic2 65.0 (25.5) 67.0 (20.8) 71.0 (20.4)
   All patients 62.3 (7.0) 55.9 (7.3) 69.1 (4.8)
General health   
   Home1 61.8 (27.8) 56.0 (24.1) 66.3 (12.6)
   Clinic2 64.4 (14.1) 58.4 (26.5) 66.2 (20.5)
   All patients 63.0 (6.5) 57.1 (7.2) 66.3 (4.7)
I-QoL   
   Home1 67.3 (19.7) 61.0 (15.9) 88.0 (15.7)
   Clinic2 80.2 (14.7) 67.0 (23.7) 77.8 (18.3)
   All patients 73.2 (18.1) 63.7 (19.0) 83.4 (16.9)*
•Baseline, ••After 6-week pause of maintenance PTNS, •••After PTNS-retreatment, *p<0.05, 
16 patients who performed self-administered maintenance PTNS at home, 25 patients who had 
maintenance PTNS in an outpatient setting
is maintenance treatment necessary?     67
discussion
The present study stresses that maintenance treatment is a necessity in success-
fully PTNS treated patients. All patients had subjective and 9 out of 11 patients 
an objective deterioration of complaints after the 6-week pause of maintenance 
therapy. Moreover, there was a signiﬁ cant deterioration of mean voided volume, 
nocturia, number of incontinence episodes and quality of life (table 2 and 3). The 
observation that not all parameters did signiﬁ cantly change is obviously caused by 
the small patient population. Furthermore, 2 patients did not respond to the inter-
ruption of maintenance PTNS or re-treatment. In retrospect, PTNS was probably 
not effective in these patients in the ﬁ rst place. 
Another explanation could be that 6 out of the 11 patients who performed self-
administered home therapy – either percutaneous or transcutaneous tibial nerve 
stimulation – could have done this suboptimally. This is supported by the ten-
dency that the voiding and quality of life parameters of the self-treatment group 
seemed to be lesser than the outpatient group. Moreover, the difference between 
the voiding and quality of life parameters at T1 and T3 seemed to be larger for the 
self-treatment group than for the outpatient group, however not signiﬁ cant. 
The difference between both groups was to be expected, since all patients of the 
self-treatment group, except one, performed transcutaneous maintenance PTNS. 
Up till now, no comparing study has been performed to determine whether trans-
cutaneous stimulation is as effective as percutaneous treatment. PTNS seems to 
be more effective, since  the electrical ﬁ eld is created between a stick-electrode 
and a needle, which is close to the tibial nerve. Low currency is needed for the 
motor response (ﬂ exing the big toe and/or fanning of the other toes) and sensory 
response (a radiating sensation at the sole of the foot and in the toes) to occur. In 
the case of transcutaneous stimulation, the electrical ﬁ eld is created between two 
surface stick-electrodes. The current has to overcome the impedance of the skin 
before it has its effect on the tibial nerve. Therefore, in theory, for transcutaneous 
stimulation a larger current is needed to evoke the motor and sensory responses 
compared to the percutaneous needle stimulation. When larger amplitude is ap-
plied, more afferent nerves located in the skin are recruited and stimulated, which 
can lead to a painful sensation. This could result in suboptimal stimulation when 
patients stimulate themselves at a well-tolerable level. 
Our results do not only support the notion that maintenance therapy is indispen-
sable to keep up positive clinical results. Obviously, such maintenance programs 
put great strains on caregivers and hospital facilities. Each patient that is put on a 
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maintenance schedule will visit the outpatients’ department at least 20 to 30 times 
per annum. This problem was the basis for new developments in the ﬁ eld of tibial 
nerve stimulation. Currently clinical work is undertaken to develop an implanta-
ble device that allows a patient to stimulate himself at home as frequently as the 
individual situation requires. In prospect, this implantable device will lessen the 
burden on medical professionals and institutions. 
conclusions
Maintenance treatment is a necessity in successfully PTNS treated patients, since 
they experience a subjective an objective deterioration of their complaints when it 
is not provided. The efﬁ cacy of PTNS is reproducible in these patients.  
conﬂ ict of interest
None declared. The study was supported by an unrestricted grant from CystoMe-
dix Inc., Anoka, MN, USA.
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abstract
Objectives 
To investigate feasibility and safety of implant driven tibial nerve stimulation. 
Methods
8 patients with refractory overactive bladder syndrome were successfully treated 
with percutaneous tibial nerve stimulation and implanted. Patients were evaluated 
with bladder diaries, quality of life questionnaires, and physical examination before 
implantation, and at 3, 6 and 12 months of follow up. The primary objective was a 
> 50% reduction of the number of incontinence episodes and/or voids on bladder 
diary. The Wilcoxon Signed Ranks Test was used. 
Results
At 3, 6 and 12 months respectively 5, 6 and 4 patients met the primary objective.  
At 3 and 6-month follow up voiding and quality of life parameters had signiﬁ cantly 
(p<0.05) improved. Urinary tract infection, temporarily walking difﬁ culties, and 
spontaneous radiating sensations were reported as adverse events but no local 
infection, erosion or dislocation. 
Conclusions
Implant driven tibial nerve stimulation seems to be feasible and safe. 
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introduction
Overactive bladder syndrome (OAB, overactive bladder wet and dry) is a common 
urological problem in many countries. It has been estimated that OAB affects ap-
proximately 17% of the adult population in Europe and the United States(1,2), with 
an estimated worldwide prevalence of 50-100 million(3). The economic burden of 
OAB can only be estimated since the disorder is underreported and often over-
looked by physicians(4). Total annual costs, including treatment and diagnosis, 
absorbent products, related medical conditions, assisted living or nursing home 
care, lost wages and cleaning expenses are estimated to range from $16 billion to 
$26 billion each year in the United States, depending on the studied age group(5,6). 
In the future the impact of OAB will probably increase even further, since the world 
population is aging(4) and the prevalence increases with age(7). 
OAB is initially treated with conservative therapy. If refractory, irreversible surgery 
can be advocated. However, this is not widespread due to high recurrence and 
complication rates(8). Percutaneous tibial nerve stimulation (PTNS) is an alterna-
tive therapy in the treatment of refractory OAB, with reported clinical success rates 
of 63-71%(8-10). It is known that PTNS maintenance therapy is a necessity in success-
fully treated patients(11), usually once every 2-3 weeks(9). This is demanding for both 
patients and outpatient departments. Therefore, it would be advantageous if the 
patients themselves at the location and time of their choice could perform main-
tenance therapy. Surface electrodes can be used for tibial nerve stimulation, as 
has been demonstrated by Andrews(12). However, there are indications that trans-
cutaneous tibial nerve stimulation may be less effective than percutaneous stimu-
lation(13). There are no randomized studies to conﬁ rm this yet, nevertheless surface 
electrodes were not considered for self-administrated maintenance treatment.
Ongoing research has led to the design and development of an innovative subcu-
taneous implant – Urgent-SQTM (CystoMedix Inc., Anoka, MN, USA) – that enables 
self-treatment. This pilot study presents results concerning the feasibility and 
safety at 12 months of follow up in 8 patients with refractory OAB.
methods
With the approval of the institutional review board 8 patients with refractory OAB 
were enrolled in a prospective pilot study between November 2002 and January 
2004. All patients gave written informed consent to the study. Implantations were 
performed in either November 2003 or January 2004.
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Methods, units and deﬁ nitions used in this study all conform to the standards 
recommended by the International Continence Society(14), except for the 24-hour 
bladder diary(15). A 24-hour bladder diary is sufﬁ cient to evaluate the patients’ 
micturition complaints(16-18). OAB was deﬁ ned as more than 7 voids and/or a sud-
den compelling urge to void, culminating in urinary leakage at least 3 times per 
24 hours on bladder diary. All medication that could inﬂ uence bladder function 
was stopped at least 2 weeks before treatment or continued without dose changes 
during the entire study. For this study speciﬁ c exclusion criteria as described by 
van Balken et al.(8) were used.
The primary objective of the study was deﬁ ned as > 50% reduction of the number 
of incontinence episodes and/or voids on bladder diary after implant driven tibial 
nerve stimulation. Apart from feasibility a secondary objective was to evaluate the 
safety of the implant.
Patients
2 male and 6 female patients (mean age 56 years, range 46-66) had had OAB com-
plaints for a mean period of 10 years (range 1-30) and were enrolled in the study. 
Prior to enrolment, patients were evaluated for OAB by history, physical examina-
tion and urological examination, including urodynamic investigation. All patients 
had an urodynamic evaluation without abnormalities, except for one  patient who 
showed late onset detrusor overactivity. All patients had been unsuccessfully 
treated with conservative treatment. 3 patients had had unsuccessful surgery 
(range 1-2 operations) for their symptoms. Colposuspension, Botulinum toxin A 
injections in the bladder and urethral dilatation were performed. All patients had 
been successfully treated with PTNS (> 50% reduction of the number incontinence 
episodes and/or voids on bladder diary). 
Method of treatment
PTNS was performed as described by van Balken et al.(8). Patients were treated with 
30-minute sessions, 3 times a week during a 4-week period. Until implantation no 
maintenance PTNS was provided for a mean period of 8 months (range 3-12).
The Urgent-SQTM consists of an external electromagnetic pulse generator with 
radio-frequency (RF) transmission capability (ﬁ gure 1) and an internal electro-
magnetic pulse receiver, the body, with two leads and monopolar electrodes, which 
are covered by medical grade silicones with the leads having platinum electrodes 
(ﬁ gure 2). The electrodes are approximately 1 cm2. The body has a diameter of 
approximately 4 cm and receives RF electromagnetic pulses from the generator 
transforming them into current pulses. Stimulation parameters are: 0-19 mA am-
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plitude, 12 or 20 Hz pulse rate and 200 msec pulse width. The maximum amplitu-
de was not altered during follow up. The pulses are biphasic and symmetrical. The 
12 Hz pulse rate was chosen, since 1 patient did only respond to PTNS at 
12 Hz. The external stimulator has to be placed directly on the skin over the inter-
nal body in order to activate it. Therefore, the amplitude will not be inﬂ uenced by 
the coil position and the internal body will not be activated by other high frequency 
devices, such as mobile telephones.  
Pre- and postoperatively prophylactic oral antibiotics (500 mg amoxicillin) were 
given. Patients were implanted in the supine position and were covered with 
sterile drapes after an antiseptic scrub of the lower leg. After spinal or general 
anaesthesia an incision of 5-7 cm was made approximately 5 cm above the medial 
malleolus, parallel to the tibia. Muscle relaxants were avoided in order not to blur 
a motor response of the foot musculature. After incising the fascia of the ﬂ exor 
tendons the electrodes were placed near the neurovascular bundle that contains 
the tibial nerve, without exposing it. The electrodes were parallelly placed and the 
distance between them was approximately 1 cm. The internal body was placed in 
a subcutaneous pocket overlying the tibia. During the procedure the implant was 
activated at regular intervals to conﬁ rm correct functioning and placement. Similar 
to percutaneous stimulation, hallux ﬂ exion can be observed when positioned cor-
rectly. If correct placement was conﬁ rmed the implant was ﬁ xed, and the wound 
was closed. 
ﬁ gure 1  The External stimulator ﬁ gure 2   The internal body with 2 leads and 
monopolar electrodes
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Motor and sensory responses were evaluated postoperatively at day 10 and at 
follow up at 3, 6 and 12 months. The responses were tested by a physician, who 
correctly placed the external stimulator and slowly increased the amplitude until 
the sensory response was present. The amplitude was further increased until the 
motor response occurred or to maximum amplitude (19 mA), which was not pain-
ful for the patients. There were no limitations to test the responses. Therapy was 
started at home postoperatively at day 10, each session lasting 30 minutes 3 times 
a week.  The stimulation was performed at the amplitude resulting in the sensory 
response and adjusted when it had faded, as has been described for PTNS(8).
Patients were evaluated by 24-hour bladder diaries, and quality of life questionnai-
res: SF-36 social function(19) and I-QoL (index of quality of life)(20) before implanta-
tion and at follow up of 3, 6, and 12 months of implant driven tibial nerve stimu-
lation. Physical examination and urinalysis were performed at all visits. X-rays in 
2 directions of the medial ankle were made 1 day and 1 month postoperatively to 
verify the position of the implant. During follow up no urodynamic evaluations 
were performed, nor was sham stimulation performed, nor were the stimulators 
turned off. Furthermore, it was not possible to determine whether the patients had 
actually treated themselves, nor changed the stimulation frequency and amplitude.
Changes in the voiding and quality of life parameters were tested on statistical 
signiﬁ cance using the Wilcoxon Signed Ranks Test.
results
After cessation of the PTNS treatment in all patients voiding and quality of life 
parameters returned to baseline values as before PTNS. 
The surgical procedure was straightforward without complications. Mean opera-
ting time was 25 minutes (range 20-30). Patients were discharged after 2 days of 
bed rest and leg elevation.  The implant was not visible from the outside.
The individual results during follow up are presented in table 1 and 2. The motor 
responses were present intra-operatively in all patients and in none at postope-
rative day 10. The sensory response (i.e. a radiating sensation at the sole of the 
foot and toes) was present 10 days postoperatively in 6 patients. 7 patients were 
treated with a frequency setting at 20 Hz and 12 Hz in 1 patient. 
implant driven tibial nerve stimulation      77
table 1  The individual results during follow up in 8 patients
 Patient
  1 2 3 4 5 6 7 8
Sex   M1 F1 F1 F1 M1 F1 F2 F1
Age (years)  49 65 66 46 50 48 62 64
Postoperative day 10  *  * *    
 Responses  m- m- m- m- m- m- m- m-
   s+ s+ s+ s+ s- s+ s- s+
 Stimulation frequency  b c a b a b c c
3 months of STNS        
 Responses  m+ m+ m+ m+ m+ m- m+ m-
   s+ s+ s+ s+ s+ s+ s+ s+
 Successful treatment  - + - - + + + +
6 months of STNS    ‡     
 Responses  m+ m+ m+ m+ m+ m- m+ m-
   s+ s+ s+ s+ s+ s+ s+ s+
 Successful treatment  + + - + + - † + +
12 months of STNS        
 Responses  m+ m+ m+ m+ m+ ** m+ m-
   s+ s+ s+ s+ s+  s+ s-
 Succesful treatment  - + - + + - + -†
+present, -absent, 120 Hz pulse rate, 212Hz pulse rate, Mmale, Ffemale, *walking difﬁ culties, 
 ‡urinary tract infection, †unexplainable loss of efﬁ cacy, **dropped out of the study, adaily stimu-
lation, bstimulation 3 times a week, cweekly stimulation, mmotor response, ssensory response 
At the 1-month follow up, X-rays showed no dislocation of the implant and no 
cable breach in any of the patients. For home-based stimulation, patients adjusted 
the stimulation schedule to their individual needs. 
At the 3-months follow up, 5 patients met the primary objective and were conside-
red a success. There was a signiﬁ cant improvement in number of voids, inconti-
nence episodes and I-Qol score (table 3). The motor and sensory responses were 
respectively present in 6 and 8 patients. 3 patients still performed implant driven 
tibial nerve stimulation 3 times per week, 2 patients once per week and 3 patients 
daily. 
78 chapter 7
table 2   Individual voiding and quality of life parameters in 8 patients at baseline, 
3 and 6 months of follow up and in 7 patients at 12 months of follow up
Parameters per 24 hour            Patient
  1 2 3 4 5 6 7 8
Number of voids        
 Baseline 16 9 15 12 23 14 8 18
 3-month follow up 10 9 9 8 9 13 6 11
 6-month follow up 7 13 13 9 11 17 8 9
 12-month follow up 9 12 16 10 9  10 15
Nocturia        
 Baseline 5 1 3 3 3 2 1 5
 3-month follow up 5 1 0 0 2 3 0 3
 6-month follow up 3 2 1 0 1 3 1 2
 12-month follow up 3 3 2 2 2  1 2
Mean voided volume (cc)        
 Baseline 104 209 120 170 17 90 127 153
 3-month follow up 135 242 233 123 27 65 117 145
 6-month follow up 114 174 133 206 32 49 114 133
 12-month follow up 156 158 222 190 44  167 142
Number of incontinence episodes        
 Baseline 0 3 0 12 0 40 6 13
 3-month follow up 0 1 0 5 0 17 2 6
 6-month follow up 0 0 0 6 0 21 0 2
 12-month follow up 0 1 0 4 0  0 8
Incontinence severity1        
 Baseline 0 2 0 2 0 1 2 2
 3-month follow up 0 1 0 1 0 1 2 2
 6-month follow up 0 0 0 1 0 1 0 2
 12-month follow up 0 1 0 1 0  0 2
Number of used pads        
 Baseline 0 3 2 4 0 6 6 2
 3-month follow up 0 2 1 2 0 5 2 3
 6-month follow up 0 2 2 0 0 6 1 2
 12-month follow up 0 2 2 2 0  2 7
I-QoL score        
 Baseline 69 88 68 62 51 47 80 48
 3-month follow up 84 97 98 71 96 61 101 52
 6-month follow up 84 105 89 80 96 52 105 81
 12-month follow up 82 99 76 81 97  99 51
10= no urine loss, 1= loss of some drops, 2= loss of small amount, 3=change of clothes due to urine 
loss
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At the 6-month follow up, 6 patients met the primary objective. Compared to the 
3-month follow up, voiding and quality of life parameters had not signiﬁ cantly 
changed except for the SF-36 domain general health (p<0.05). Compared to before 
implantation, number of incontinence episodes, I-QoL score (table 3), and SF-36 
domains social function and vitality had signiﬁ cantly (p<0.05) improved. Compa-
red to the results after PTNS, voiding and quality of life parameters were similar, 
except for mean voided volume, which had signiﬁ cantly decreased  (p<0.05). 
Patients had not changed their treatment schedule. 
At the 12-month follow up, 5 patients had improved on bladder diary and 4 of these 
patients met the primary objective. Compared to the data before implantation and 
at 6-month follow up there were no signiﬁ cant changes in the voiding and quality 
of life parameters. Compared to the results of PTNS, voiding and quality of life 
parameters were similar and without signiﬁ cant differences. The motor response 
was present in 6 and the sensory response in 7 patients. Patients had not changed 
their treatment schedule.  All patients who completed the 1-year follow up were 
satisﬁ ed with the results of the implant. 
table 3   Voiding and quality of life parameters before implantation, at 3 and 6 months of 
implant driven tibial nerve stimulation in 8 patients, and at 12 months in 7 patients
Parameters per 24 hours                             Mean (SD)
 Before 3-month 6-month 12-month of
implantation follow up follow up  follow up
Number of voids 14.4 (4.9) 9.4 (2.1)* 10.9 (3.3) 11.6 (2.9)
Nocturia 2.9 (1.6) 1.8 (1.8) 1.6 (1.1) 2.1 (0.7)
Mean voided volume (cc) 123.8 (57.6) 135.9 (73.9) 119.4 (58.0) 154.1 (55.3)
Number of incontinence 9.3 (13.5) 3.9 (5.8)* 3.6 (7.3)* 1.9 (3.0)
episodes
Number of used pads 2.9 (2.4) 1.9 (1.6) 1.6 (2.0) 2.1 (2.3)
I-QoL score 64.1 (15.1) 82.5 18.9)* 86.5 17.1)* 83.6 (17.2)
*compared to before implantation and p<0.05
Directly after the operation 3 patients reported difﬁ culties when walking or stan-
ding on the operated leg due to wound pain. Two of these patients received phy-
siotherapy for their complaints, which  had disappeared within 2-3 weeks without 
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further intervention. Moreover, these patients had not used the prescribed anal-
gesics. Postoperatively, 7 patients reported spontaneous radiating sensations (i.e. 
sensory response without activation of the implant), which disappeared without 
any intervention within 3 months in all patients except one. Before the 3-month 
follow up and at 6 months one patient had a urinary tract infection, which was 
treated with antibiotics.  During follow up no other adverse events were reported, 
such as local infection, dislocation or erosion. The adverse events are summarised 
in table 4.
table 4   Reported adverse events in 8 implanted patients during 12 months of  follow up
Adverse events Number of patients
Walking difﬁ culties 3
Spontaneous sensory response 7
Urinary tract infection 2
At 6 months of implant driven tibial nerve stimulation, one patient had an unex-
plainable loss of efﬁ cacy while still having the sensory response (the motor respon-
se had been present only intra-operatively). Technical problems like lead disloca-
tion were ruled out on X-ray. However, lead wire breach  can not be ruled out since 
no surface mapping was performed. Switching the stimulation frequency to 12 Hz 
had no result; neither had PTNS re-treatment. Afterwards the patient dropped out 
of the study and the treatment was considered unsuccessful.  
At 12-month follow up, another patient had an unexplainable loss of efﬁ cacy. This 
patient had lost the sensory response to the implant driven tibial nerve stimu-
lation (the motor response had only intra-operatively been present). Technical 
(dislocation) and physical causes were ruled out on respectively X-ray and physical 
examination, including neurological examination. However, since no surface map-
ping was performed, therefore lead wire breach can not be ruled out. The patient 
was successfully re-treated with PTNS. Afterwards, the Urgent-SQTM was explanted 
at the patients’ request. During explantation the implant was activated, which did 
not result in a motor response. The device was examined; however no results are 
available yet. 
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discussion
Implant driven tibial nerve stimulation seems to be feasible, since both sensory 
and motor responses were present postoperatively. The occurring loss of the mo-
tor response at maximal amplitude (temporarily in 6 and lasting in 2 patients) may 
have been caused by edema and/or ﬁ brosis around the electrodes, since after the 
edema had disappeared the response occurred in 6 out of the 8 patients. 
At 3, 6 and 12 months of follow up, respectively 5, 6 and 4 patients were success-
fully treated. The fact that not all voiding and quality of life parameters improved 
signiﬁ cantly at follow up can most probably be explained by the small number 
of patients included in this pilot study, the fact that at the 6-month evaluation 
one  patient had a urinary tract infection (the patient was not re-evaluated after 
treatment) and by the unexplainable loss of stimulation efﬁ cacy in 2 patients at 
6 and 12 months of follow up. Moreover, when the data at 6 months of implant 
driven tibial nerve stimulation are corrected for the urinary tract infection and the 
unexplainable loss of efﬁ cacy, these are similar to the data after PTNS. 
Due to the small patient population it was impossible to determine whether the 
preoperative urodynamic outcome correlates with the efﬁ cacy of the implant. 
However, it is to be expected that patients with urodynamic stable bladders or late 
onset detrusor overactivity are the best candidates for implant driven tibial nerve 
stimulation, as has been described for PTNS(21). 
Also, because of the small patient population, it was impossible to determine 
whether the presence of the motor and/or sensory responses correlates with the 
efﬁ cacy of the implant. To date this has not been determined for PTNS either. 
Percutaneous tibial nerve stimulation is performed at an amplitude resulting in 
the sensory response with adjustment of the amplitude when the response has 
faded(8,9). Moreover, stimulation at amplitude resulting in the motor response is 
too painful for most patients. Therefore, implant driven tibial nerve stimulation 
was performed similar to PTNS. As with PTNS, implant driven stimulation at the 
level of the motor response is too painful for most patients.
The observation that not all patients who respond well on percutaneous stimula-
tion do the same on subcutaneous stimulation, is known from studies concerning 
sacral nerve stimulation; the same goes for loss of efﬁ cacy(22-24). The difference 
between percutaneous and implant driven tibial nerve stimulation could be that 
for implant driven stimulation it was impossible to determine whether the patients 
had actually treated themselves or not. Moreover the stimulation amplitude was 
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not recorded, so it is possible that the patients had treated themselves at too low 
amplitude. Another possibility is that the placebo effect is larger for implant driven 
tibial nerve stimulation than for PTNS. For the latter a randomized double-blinded 
placebo-controlled study is being performed to determine whether PTNS is more 
than a placebo effect; however results are not available jet. It seems likely that 
the PTNS placebo effect is similar to that of pharmacotherapy in the treatment of 
OAB.  Pharmacotherapeutic placebo-controlled trials have reported placebo effects 
of 28-43% in patients with urge urinary incontinence(25-27). A larger study is needed 
to make conclusions concerning the efﬁ cacy of the implant.
Patients were discharged after 2 days, which is a relatively long period for such 
a procedure. This was caused by the fact that these patients were the ﬁ rst to be 
operated on, which led to increased caution. Probably we were too careful and we 
anticipate that future patients will be discharged at the same day. 
During the 12-month follow up implant driven tibial nerve stimulation proved to 
be safe. No local infection, spontaneous dislocation or erosion of the Urgent-SQTM
had occurred during follow up. Postoperatively, 3 patients had walking difﬁ culties 
due to pain caused by the surgery. These complaints had disappeared completely 
within 2-3 weeks. Moreover, these patients used no the prescribed analgesics. Du-
ring the 12-month follow up 2 patients had a urinary tract infection. These patients 
were known to have had some recurrent urinary tract infections in the past. 7 pa-
tients postoperatively mentioned a sudden radiating sensation, which disappeared 
without intervention within 3 months in all patients except one. In this patient the 
sudden radiating sensations are still present, but occur rarely. Long-term follow up 
is needed to determine the safety of the implant during chronic use.
Other implantable devices are available for neuromodulative treatment of  lower 
urinary tract dysfunction(28-30). For all devices a pre-operative eligibility test is 
 performed to determine whether the patient is a deemed candidate. Of these 
implantable devices sacral nerve stimulation (SNS) has proven to be effective and 
safe(30-33). Side effects have been reported such as pain in the buttocks, pelvic area, 
lower extremities and at the pulse generator (Interstim®, Medtronic,  Minneapolis, 
Minnesota, USA) site, lead migration, infection at test stimulation lead site, 
transient electric shock, re-operations due to technical problems and adverse 
change of urinary, bowel or sexual function(30-36). For pudendal nerve stimulation 
by the Bion® microstimulator (Advanced Bionics Corp., Valencia, CA), vaginal 
fungus infection, allergic reaction, vaginal dryness during intercourse, mechanical 
irritation during bicycle riding and altered bowel functions(28) have been reported. 
Skin erosion at the connection site between lead and extension cable for pudendal 
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nerve stimulation by deﬁ nitive quadripolar tined lead, as is used for SNS(29). For 
PTNS minimal hematoma and transient pain at the insertion site have been des-
cribed(9,37). The Urgent-SQTM could be an alternative.  Implant driven tibial nerve 
stimulation is minimal invasive and adverse events like infection or dislocation 
did not occur in this study. Furthermore, the internal body contains no internal 
battery that has to be replaced in time, as is the case with SNS and the devices for 
pudendal nerve stimulation. Patients experience no mechanical problems due to 
the implant, which is invisible at the outside.  Finally, during the 12-month follow 
up only urinary tract infection, transient walking difﬁ culties and spontaneous sen-
sory responses were reported as adverse events.  All patients who completed the 
1-year follow up were satisﬁ ed with the result. In order to deﬁ ne the proper place of 
the Urgent- SQTM in the treatment of lower urinary tract dysfunction, comparative 
studies are needed.  
conclusions
Implant driven tibial nerve stimulation with the Urgent-SQTM device seems to be 
feasible and safe during short-term follow up in patients with refractory OAB.  
A study with a larger population and long-term follow up has to be performed to 
determine the efﬁ cacy and long-term safety of the implant. 
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summary and conclusions
chapter 1 provides the introduction to the present thesis, which contains a descrip-
tion of lower urinary tract dysfunction and the different therapies. Furthermore, the 
aims of this thesis are presented.
chapter 2 discusses the physiology and the innervation of the bladder, as well as 
the continence and micturition processes.
chapter 3 presents the current opinion on the working mechanism of neuromo-
dulation. An overview is presented of the different theories and research into the 
physiological background of neuromodulation in the last 35 years, with emphasis 
on recent developments. It can be concluded that in the treatment of stress incon-
tinence neuromodulation probably induces physiological changes in the sphincter 
muscles and pelvic ﬂ oor. In the treatment of overactive bladder syndrome, non-
obstructive voiding dysfunction and chronic pelvic pain the mechanism of action 
seems to be more complicated. Most likely it is a combination of the different 
suggested modes of action, involving the neuroaxis at different levels.
chapter 4 investigates whether PTNS can modulate the micturition reﬂ ex in an 
anaesthetised female cat model. Moreover, it is determined whether the sacral 
plexus is involved in the working mechanism of PTNS. It can be concluded that 
the cat model is suitable to investigate the effect of PTNS on the micturition 
reﬂ ex. It was demonstrated that PTNS modulates the micturition reﬂ ex, since the 
volume at which the micturition reﬂ ex occurred (micturition reﬂ ex volume, MRV) 
had increased from 54 ml (SD 26) at baseline to 71 ml (SD 30, p= 0.001) during 
 stimulation. This effect was reversible, since mean MRV returned to 54 ml (SD 27, 
p= 0.002) in the continued cystometries. The effect of median nerve stimulation 
on the micturition reﬂ ex was investigated to determine the involvement of the 
 sacral plexus in the working mechanism of PTNS, since both the median nerve 
(C6-8) and the tibial nerve (L4-S3) contain sensory and motor nerve ﬁ bres. Stimu-
lation of the median nerve had no effect on MRV, indicating that the sacral plexus 
seems to be involved in the modulation process of tibial nerve stimulation.
chapter 5 investigates the assumption that the improved quality of life in PTNS 
treated patients is due to improved voiding parameters. It can be concluded that 
the improved voiding parameters do result in an improved quality of life in PTNS 
treated patients with refractory urge urinary incontinence.  There was a signiﬁ cant 
(p<0.05) correlation between several quality of life parameters and voiding para-
meters. This indicates that PTNS has a useful place in the treatment of refractory 
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urge urinary incontinence (overactive bladder wet) and should at least be consi-
dered as a therapeutic alternative before turning to aggressive surgery. Patients 
must have a reduction of at least 2 used pads before their quality of life impro-
ves. This could be the best deﬁ nition of successful therapy for patients with urge 
 urinary incontinence.
chapter 6 investigates whether maintenance treatment is necessary in successfully 
PTNS treated patients and whether successful treatment can be reproduced. It 
can be concluded that maintenance PTNS is a necessity in successfully treated 
patients with refractory OAB and that the efﬁ cacy of PTNS can be reproduced in 
formerly successfully treated patients. After pausing the maintenance treatment 
for a period of 6 weeks 7/11 patients (64%) had a > 50% increase of the number of 
incontinence episodes and/or micturition frequency on bladder diary. Mean voided 
volume, nocturia, number of incontinence episodes and incontinence severity 
had signiﬁ cantly (p<0.05) deteriorated. After re-treatment 9/11 patients (82%) had 
a > 50% reduction of the number of incontinence episodes and/or micturition 
frequency on bladder diary. Moreover, nocturia, number of incontinence episodes, 
incontinence severity, mean voided volume and quality of life had signiﬁ cantly 
(p<0.05) improved.
chapter 7 investigates whether implant driven tibial nerve stimulation is feasible 
and safe in the treatment of refractory OAB. It can be concluded that implanted 
driven tibial nerve stimulation is feasible and safe during 1-year follow up. The 
implantation of the Urgent SQTM itself was straightforward and without compli-
cations. Urinary tract infection, temporarily walking difﬁ culties, and spontaneous 
 radiating sensations were reported as adverse events during follow up, but no local 
infection, erosion or dislocation. Moreover voiding and quality of life para meters 
had signiﬁ cantly (p<0.05) improved.  At 3, 6 and 12 months of implant driven tibial 
nerve stimulation, respectively 5, 6 and 4 patients out of the 8 implanted patients 
had a > 50% reduction of the number of incontinence episodes and/or voids on 
bladder diary.
general conclusions and future perspectives
PTNS seems to be effective since there is a correlation between the signiﬁ cantly 
improved voiding parameters and quality of life (chapter 5). Moreover, these 
parameters deteriorate signiﬁ cantly when maintenance treatment is not provided, 
and successful treatment can be reproduced (chapter 6).  Furthermore, animal 
studies in cats demonstrate that the micturition reﬂ ex can be modulated by PTNS 
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 (chapter 4). It is tempting to extrapolate these results, since there are strong indi-
cations that at the brainstem and diencephalic level micturition is organized in the 
same way in humans(1). However, to provide irrefutable proof that PTNS is more 
than a placebo effect randomized studies are needed. A randomized double-blin-
ded placebo-controlled trial is being performed, but results are not available yet. 
When these results come available, the proper place of PTNS in the treatment of 
lower urinary tract dysfunction can be determined. 
The ﬁ rst results of implant driven tibial nerve stimulation seem to be promising 
(chapter 7). However, studies with a larger population and long-term follow up are 
needed to determine the efﬁ cacy and long-term safety of the implant. Moreover, 
the Urgent-SQTM is not the only available implant for neuromodulative 
treatment(2-4). Comparative studies should be performed to deﬁ ne the proper place 
of the Urgent- SQTM.   
Until it has been determined whether tibial nerve stimulation has a place in the 
treatment of lower urinary tract dysfunction, PTNS should be at least considered 
before irreversible surgery is advocated. The treatment is safe, minimal invasive 
and not costly. When the proper place of PTNS has been established a consensus 
should be made on treatment indications, patient selection and treatment protocol 
(i.e. stimulation parameters, treatment schedules, evaluation methods and deﬁ ni-
tion of successful treatment). And ﬁ nal, further research should be performed on 
the mechanism of action to investigate whether for instance increased sympathetic 
activity is involved or suprasacral (i.e. pontine and/or cortical) areas, as has been 
suggested by several authors(5;6). 
The future directives of neuromodulation in general are very similar to those of 
tibial nerve stimulation. A consensus is needed on treatment indications, patient 
selection and treatment protocol. Further research is necessary to determine the 
mechanisms of action, the efﬁ cacy and the proper place of neuromodulation in the 
treatment of lower urinary tract dysfunction. Final, more selective or event-driven 
(detrusor overactivity or desire to void) stimulation should be investigated at more 
peripheral sites and with less invasive devices(7).
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samenvatting en conclusies
hoofdstuk 1 vormt de inleiding van dit proefschrift. Hierin wordt beschreven wat 
disfunctie van de lagere urinewegen en de behandeling ervan inhouden. Tot slot 
worden de doelstellingen van het proefschrift beschreven. 
hoofdstuk 2 geeft beschrijvingen van de fysiologie en de innervatie van de blaas. 
Daarnaast worden de processen van continentie en mictie besproken. 
hoofdstuk 3 geeft een overzicht van de diverse theorieën over en het onder-
zoek naar de fysiologische achtergrond van neuromodulatie van de afgelopen 
35 jaar. Hierbij ligt de nadruk op recente ontwikkelingen. Neuromodulatie in de 
behandeling van stress-incontinentie induceert zeer waarschijnlijk fysiologische 
veranderingen in de spiercellen van de blaassluitspier en de bekkenbodem. Bij de 
behandeling van de overactieve blaas, niet-obstructieve blaasretentie en chronisch 
bekkenpijn-syndroom lijkt het werkingsmechanisme ingewikkelder te zijn. Het 
betreft naar alle waarschijnlijkheid een combinatie van de verschillende veron-
derstelde werkingsmechanismen waarbij de neuroaxis op verschillende niveaus 
betrokken is. 
In hoofdstuk 4 wordt onderzocht of het kattenmodel een geschikt diermodel is 
om het effect van PTNS op de mictiereﬂ ex te bepalen. In de eerste plaats wordt 
nagegaan of PTNS de mictiereﬂ ex kan moduleren. Tevens wordt onderzocht of 
de sacrale zenuwplexus betrokken is bij het werkingsmechanisme. De studie laat 
zien dat PTNS inderdaad de mictiereﬂ ex van de kat kan moduleren, aangezien 
het volume waarop de mictiereﬂ ex optreedt (mictiereﬂ ex volume, MRV) toenam 
van gemiddeld 54 ml (SD 26) in de uitgangssituatie naar gemiddeld 71 ml (SD 
30, p= 0.001) tijdens stimulatie. Dit effect is omkeerbaar, aangezien in de daar-
opvolgende cystometrieën het MRV gemiddeld 54 ml (SD 27, p= 0.002) was. Het 
effect van de nervus medianus stimulatie werd onderzocht om te bepalen of de 
sacrale zenuwplexus betrokken is bij het werkingsmechanisme van PTNS, aange-
zien zowel de nervus medianus (C6-8) als de nervus tibialis (L4-S3) sensorische en 
motorische zenuwvezels bevat. Stimulatie van de nervus medianus had geen effect 
op het MRV, wat betekent dat de sacrale zenuwplexus zeer waarschijnlijk betrokken 
is in het modulatieproces van PTNS. 
hoofdstuk 5 gaat in op de veronderstelling dat verbetering van de mictieparame-
ters leidt tot een verbeterde kwaliteit van leven bij patiënten die met PTNS zijn be-
handeld. Deze studie bevestigt die veronderstelling. Er is een signiﬁ cante (p<0.05) 
correlatie tussen verscheidene mictieparameters en de kwaliteit van leven. De 
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studie geeft dan ook aan dat PTNS een plek heeft in de behandeling van urge-in-
continentie die niet reageert op de conservatieve behandeling (refractaire urge-in-
continentie) en op zijn minst overwogen moet worden voordat wordt overgegaan 
op agressieve chirurgie. De kwaliteit van leven van deze patiënten verbetert indien 
ze minimaal 2 verbandjes per dag minder gebruiken. Dit zou wel eens de beste 
deﬁ nitie van succesvolle therapie kunnen zijn.
In hoofdstuk 6 wordt onderzocht of een onderhoudsbehandeling noodzakelijk 
is voor patiënten met een refractaire overactieve blaas die succesvol zijn behan-
deld met PTNS. In de studie komt naar voren dat een onderhoudsbehandeling 
inderdaad noodzakelijk is en dat de effectiviteit van de behandeling reproduceer-
baar is. Na onderbreking van de onderhoudsbehandeling voor een periode van 
6 weken bleken 7 van de 11 patiënten (64%) een > 50% toename te hebben van 
de mictiefrequentie en/of het aantal incontinentie episodes op de mictielijsten. 
Het gemiddeld geplaste volume, nycturie, het aantal incontinentie episodes en de 
ernst hiervan waren signiﬁ cant (p<0.05) verslechterd. Na herbehandeling hadden 
9 van de 11 patiënten (82%) een > 50% afname van de mictiefrequentie en/of het 
aantal incontinentie-episodes op de mictielijsten. Daarnaast waren het gemiddeld 
geplaste volume, nycturie, het aantal incontinentie-episodes en de ernst hiervan 
en, tot slot, de kwaliteit van leven signiﬁ cant (p<0.05) verbeterd. 
In hoofdstuk 7 wordt onderzocht of stimulatie van de nervus tibialis met behulp 
van een implantaat, Urgent-SQTM, mogelijk en veilig is. Na een follow up van 1 jaar 
kan worden geconcludeerd dat stimulatie van de nervus tibialis met behulp van 
het implantaat inderdaad mogelijk en veilig is. De implantatie van de Urgent-SQTM
verliep eenvoudig en zonder complicaties. Tijdens follow up werden urinewegin-
fectie, tijdelijke loopproblemen en spontane tintelingen onder de voetzool gemeld 
als bijwerkingen. Lokale infectie, erosie of dislocatie van het implantaat deden zich 
niet voor. Er was een signiﬁ cante (p<0.05) verbetering van de kwaliteit van leven 
en de mictieparameters. 3, 6 en 12 maanden na implantatie hadden respectievelijk 
5, 6 en 4 van de 8 geïmplanteerde patiënten een > 50% afname van de mictiefre-
quentie en/of het aantal incontinentie-episodes op de mictielijst. 
algemene conclusies en toekomstperspectieven
Percutane stimulatie van de nervus tibialis lijkt effectief te zijn, aangezien er een 
correlatie is tussen de signiﬁ cant verbeterde mictieparameters en de kwaliteit van 
leven van de behandelde patiënten (hoofdstuk 5). Bovendien verslechteren deze 
parameters signiﬁ cant als de onderhoudsbehandeling wordt gestopt en kan het 
effect van de behandeling worden gereproduceerd (hoofdstuk 6). Verder toont 
het dieronderzoek met katten aan dat PTNS de mictiereﬂ ex inderdaad moduleert. 
Het is zeer verleidelijk om deze resultaten naar de mens te vertalen, aangezien 
er sterke aanwijzingen zijn dat bij katten en mensen de mictie op het niveau van 
de hersenstam en het diencephalon op dezelfde wijze wordt gereguleerd(1). Er 
zijn echter gerandomiseerde studies nodig om onweerlegbaar aan te tonen dat 
PTNS meer is dan een placebo-effect. Een gerandomiseerde dubbel-geblindeerde 
placebo-gecontroleerde studie wordt momenteel uitgevoerd, maar de resultaten 
zijn nog niet beschikbaar. Wanneer deze beschikbaar komen, kan de juiste plaats 
van PTNS in de behandeling van refractaire disfunctie van de lagere urinewegen 
worden bepaald. 
De eerste resultaten van nervus tibialis stimulatie met behulp van een implantaat 
zijn veelbelovend (hoofdstuk 7). Er zijn echter studies met een grotere patiënten-
populatie en een langere follow up nodig om de effectiviteit en de veiligheid op de 
lange termijn te bepalen. Bovendien is de Urgent-SQTM niet het enige beschikbare 
implantaat voor neuromodulatieve behandeling van lagere urineweg disfunctie(2-4). 
Vergelijkende studies zijn dan ook nodig om de juiste plaats van de Urgent-SQTM
te bepalen.
Totdat duidelijk is of nervus tibialis stimulatie een plaats heeft in de behande-
ling van lagere urineweg disfunctie, moet PTNS op zijn minst overwogen worden 
voordat wordt overgegaan tot onomkeerbare chirurgie. De behandeling is immers 
veilig, minimaal invasief en niet duur.  Als duidelijk is dat nervus tibialis stimu-
latie inderdaad een plaats heeft in de behandeling van deze klachten, moet er 
eenduidigheid komen ten aanzien van de behandelindicaties, patiëntenselectie en 
behandelprotocollen (stimulatieparameters, behandelschema’s, evaluatiemetho-
des en de deﬁ nitie van een succesvolle behandeling). Tot slot is meer onderzoek 
nodig naar het werkingsmechanisme; bijvoorbeeld naar verhoogde sympatische 
activatie en suprasacrale gebieden in de hersenen (hersenstam en cortex), zoals 
door diverse auteurs wordt gesuggereerd(5,6). 
De toekomstverwachtingen voor neuromodulatie in algemene zin zijn vrijwel 
gelijk aan die van nervus tibialis stimulatie. Er is consensus nodig ten aanzien van 
de behandelindicaties, patiëntenselectie en behandelprotocollen. Tevens is meer 
onderzoek nodig naar het werkingsmechanisme, de effectiviteit en de plaats van 
neuromodulatie in de behandeling van refractaire lagere urineweg disfunctie. Tot 
slot is onderzoek nodig naar meer selectieve stimulatie of het stimuleren tijdens 
het optreden van blaasoveractiviteit of drang tot mictie. Daarbij moet ook geke-
ken worden naar stimulatie op meer perifere plaatsen en met behulp van minder 
invasieve apparatuur(7).
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het feit dat ik af en toe terug kon vliegen naar het oude nest, nog altijd een baken 
van rust. 
Lieve Roel: bedankt dat je mij hebt leren schrijven en voor de lol die ik er in heb 
gekregen. Door het lezen van de artikelen ben je volgens mij een halve uroloog 
geworden. Waar ik je nog het meest dankbaar voor ben is jouw onvoorwaardelijke 
liefde en geduld, ook als het tegen zat. Je weet nu hoe het moet en welke valkuilen 
je moet vermijden...veel plezier met het afronden van je eigen proefschrift. Ik ben 
erg benieuwd wat je er mee gaat doen.
curriculum vitae
Floor van der Pal werd geboren op 27 januari 1975 te Oldenzaal. In 1993 behaalde 
zij het VWO-diploma aan het Thij-college in diezelfde plaats. Daarna begon zij 
aan de studie Geneeskunde aan de Faculteit der Medische Wetenschappen van de 
Katholieke Universiteit Nijmegen, waar zij in 1998 met goed gevolg het doctoraal 
examen aﬂ egde. Tijdens de daaropvolgende co-schappen werd haar interesse voor 
de urologie gewekt, wat bevestigd werd door haar keuze-co-schap op de afde-
ling urologie in het Bosch Medicentrum te ’s-Hertogenbosch (begeleider Dr. J.W. 
Hoekstra) en haar wetenschappelijke stage op de afdeling urologie van het UMC 
St. Radboud ziekenhuis (begeleider Dr. J.A. Witjes). In 2001 behaalde zij het arts-
examen en ging zij als AGNIO aan de slag op de afdeling urologie van het Bosch 
Medicentrum te ’s-Hertogenbosch (Opleider Dr. J.W. Hoekstra). Tijdens deze peri-
ode werkte zij mee aan onderzoek naar de effectiviteit van nervus tibialis stimulatie 
in de behandeling van interstitiële cystitis. De resultaten van dit onderzoek werden 
gepresenteerd tijdens een bijeenkomst van de SANS-usersclub: hier werden tevens 
de eerste bouwstenen voor dit proefschrift gelegd. Van 1 april 2002 tot en met 
december 2005 was zij als arts-onderzoeker verbonden aan de afdeling urologie 
van het UMC St. Radboud ziekenhuis te Nijmegen. Tijdens deze periode verrichtte 
zij het onderzoek dat tot dit proefschrift heeft geleid en werd zij aangenomen voor 
de opleiding urologie (cluster Nijmegen, opleider Prof. Dr. F.M.J. Debruyne). Op 
1 januari 2006 is zij gestart met de vooropleiding op de afdeling chirurgie van het 
Rijnstate ziekenhuis te Arnhem (opleider: Dr. J.H.G. Klinkenbijl).
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